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ABSTRACT 
 
Besides the oncotic function Human serum Albumin (HSA) is also endowed with 
many other non-oncotic properties among which the antioxidant activity. Beside 
quantitative changes, during cirrhosis extensive post-transcriptional alterations, likely 
promoted by pro-inflammatory and pro-oxidant state occur to the HSA molecule. In 
this study we evaluated the structural and functional integrity of HSA in a large series 
of hospitalized patients with advanced cirrhosis. We also evaluated the relationship 
between alterations to the HSA molecule and clinical features as well as 1-year 
prognosis of patients included in the study.  
By using an LC-ESI-MS approach we identified several HSA isoforms characterized 
by one or more structural defects. These alterations mainly involved the cysteine-34 
residue, the main antioxidant site of the molecule, and were mainly promoted by a 
pro-oxidant environment. Specific patterns of molecular alterations were found 
associated to the severity of cirrhosis and to the presence of clinical complication of 
disease, while the residual amount of the native HSA emerged as a potent predictor of 
1-year mortality.  
The functional integrity of the N-terminal portion of the HSA molecule, provided with 
an indirect antioxidant activity, was evaluated by measuring the circulating level of 
Ischemia Modified Albumin (IMA) and IMA to serum albumin ratio (IMAr). IMA and 
IMAr were not associated to the severity of cirrhosis nor to the patients prognosis. 
Contrariwise IMA and IMAr were specifically associated to bacterial infection, 
showing a discriminating performance comparable to that of C-reactive protein.  
In conclusion this study provided evidences of clinical and prognostic relevance of 
HSA structural and functional alteration in patients with cirrhosis, strengthening the 
concept that the global function of the HSA molecule, resulting from both oncotic and 
non-oncotic properties, is related not only to its absolute circulating level, but also, 
and perhaps mainly, to its structural and functional integrity.  
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LIST OF ABBREVIATIONS 
 
 
HSA: human serum albumin; 
HSA-L: C-terminal truncated (-Leu) human serum albumin; 
HSA-DA: N-terminal truncated (-Asp-Ala) human serum albumin; 
HSA+SO2H: sulfinylated human serum albumin; 
HSA+CYS: cysteinylated human serum albumin; 
HSA+GLYC: glycosylated human serum albumin; 
HSA+ CYS+GLYC: cysteinylated and glycosylated human serum albumin; 
dHSA-DA: dimeric N-terminal truncated (-Asp-Ala) human serum albumin; 
dHSA-L: dimeric C-terminal truncated (-Leu) human serum albumin; 
dHSA: dimeric native form of human serum albumin; 
IMA: ischemia modified albumin; 
IMAr: ischemia modified albumin ratio; 
ESI-MS: electrospray ionization mass spectrometry; 
HPLC: high performance liquid chromatography; 
LC-MS: liquid chromatography-mass spectrometry; 
PH: portal hypertension; 
BT: bacterial translocation; 
MELD: Model for End stage Liver Disease.
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INTRODUCTION 
 
1. The clinical scenario: liver cirrhosis 
Liver cirrhosis is the consequence of a chronic liver injury due to different etiological 
agents, among which hepatic viruses and alcohol are the most frequent1. It is 
characterized by a severe tissue fibrosis that leads to a conversion of normal liver 
architecture leading to the formation of structurally abnormal regenerative nodules. 
Cirrhosis is an increasing cause of morbidity and mortality in developed countries. It is 
the 14th most common cause of death in adults worldwide but the fourth in central 
Europe; it results in 1·03 million deaths per year worldwide, 170 000 per year in 
Europe2. In most of cases the only solution for the patients affected by cirrhosis is liver 
transplantation, and in Europe this pathology is the main indication for 5500 transplants 
per year. Different are the causes of liver cirrhosis and they vary in different area of the 
world. Alcoholic liver disease and hepatitis C are the most common causes in developed 
countries, whereas hepatitis B is the prevailing cause in most parts of Asia and sub-
Saharan Africa. Liver cirrhosis could be also a consequence of genetic disorder such as 
haemochromatosis or Wilson’s disease. In some cases cirrhosis develops in absence of a 
clearly defined etiological agent, this was defined as cryptogenic cirrhosis. Additional 
risk factors for the progression of the disease were metabolic disorders such as type 2 
diabetes, hypertension and hyperlipidemia (all features of the metabolic syndrome). 
They all contribute to the progression of  non-alcoholic steatohepatitis leading finally to 
the development of cirrhosis 3. 
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1.1. Natural history of liver cirrhosis  
Chronic liver injury of different etiology leads to the perpetuation of the normal wound 
healing response which ultimately causes an abnormal continuation of the fibrogenic 
process. In this setting the onset of regenerative nodules surrounded by fibrous band 
represents the main pathological feature based on which histological diagnosis of 
cirrhosis is made 4. 
Portal hypertension (PH) represents the earliest consequence of cirrhosis and underlies 
most of the clinical complications of the disease. PH results from an increased 
intrahepatic resistance due to architectural distortion, endothelial dysfunction, 
intrahepatic vascular shunts between afferent and efferent vessels of the liver, and 
furthermore to an increase in portal blood flow2. 
Endothelial dysfunction is due to inhibitors of nitric oxide synthase and an increased 
production of vasoconstrictors that further cause a rise of hepatic resistance to blood 
flow and portal pressure5. An increase of portal venous inflow is the result of a marked 
arteriolar vasodilatation in the splanchnic region draining into the portal vein6. 
Splanchnic vasodilatation (SV) is a consequence of PH and principally related to an 
abnormal production of vasodilator substances such as nitric oxide, carbon monoxide, 
glucagon, vasodilator peptides, endocannabinoids, etc. This event leads to the attraction 
of blood towards the splanchnic vascular bed causing a reduced effective arterial blood 
volume. In this setting an enhancement of cardiac contractility and cardiac output7 
counterbalance the vascular resistances and maintain arterial blood volume. The fall of 
effective arterial blood volume causes the activation of compensatory neurohormonal 
vasoconstrictor systems such as the renin-angiotensin-aldosterone system (RAAS), the 
sympathetic nervous system (SNS), and arginine vasopressin. The response of these 
activated systems consists in retention of water, sodium and specific organ 
vasoconstriction, that cause the onset of typical complications  which characterize the   
decompensate phase of cirrhosis8. What explained above represents the 
pathophysiological mechanisms of liver cirrhosis referred to the peripheral arterial 
vasodilatation hypothesis (PAVH), a theory formulated in 1988, in which the splanchnic 
arterial vasodilatation constitutes the primary pathogenic event responsible for 
hypovolemia, cardiac abnormalities and finally complications such as ascites and renal 
impairment9. Considering new findings and progress in the knowledge of liver 
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pathophysiology a new hypothesis has been stated10 .Such new findings attribute to the 
translocation of Gram negative bacteria across the intestinal wall, and to the resulting 
systemic inflammation, a central role in the development of vascular alteration which 
leads to the decompensation of cirrhosis (Figure. 1). Following bacterial translocation, 
the bacterial product, defined as pathogen-associated molecular patterns (PAMPs), 
released in the vascular compartment are recognized by pattern recognition receptors 
(PRRs) mainly expressed on immune cells10. The activation of PPRs leads to the 
production of pro-inflammatory cytokines such as interleukin 6 (IL6) and Tumor 
necrosis Factor α (TNFα) . The main targets for PAMPs are arterial wall and heart 
where they induce the production of vasodilators as nitric oxide instead for the heart 
they induce myocardial dysfunction10. Thus the activation of the host innate immune 
response triggers endothelial molecular mechanisms responsible for arterial 
vasodilatation, and also promote organ damage with a storm of pro-inflammatory 
cytokines and reactive oxygen and nitrogen species10.  
 
 
 
 
Figure 1. Mechanism leading to decompensation and organ failure in patients with 
cirrhosis. Bacterial translocation (BT) progressively impacts the natural course of 
cirrhosis, from the pre-ascitic compensated stage to advanced decompensation and 
hepatorenal syndrome. SAV, splanchnic arterial vasodilatation. Bernardi, M. et al, J. 
Hepatol. 2015, 63:1272–84. 
 
As outlined above the occurrence of clinical complications and the increase in portal 
pressure define two different phases in the natural history of cirrhosis defined as 
compensated and decompensated cirrhosis. The compensated phase might last for years 
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and is characterized from an absence of overt clinical manifestation and an hepatic vein 
pressure gradient (HVPG) still within a range of 5–10 mmHg. In clinical practice, 
HVPG represents an indirect measure of portal pressure and it is the best predictor of 
the development of PH.  
The switch to decompensated cirrhosis occurs at onset of clinical complications and 
HVPG amounts to values more than 10–12 mmHg11. Clinical manifestations of hepatic 
decompensation consist in ascites formation, hepatorenal syndrome, variceal bleeding, 
pulmonary complications and hepatic encephalopathy5. Once the complication appeared 
the diagnosis is almost immediate, an ultrasonography or a magnetic resonance is a 
sufficient tool to confirm the ongoing liver cirrhosis. Instead, for the early cirrhosis, the 
canonical  imaging could lead to false negative, so noninvasive markers of fibrosis are 
increasingly used like direct/indirect serum marker (AST/ALT) or new imaging 
modality such as Fibroscan or Fibrotest. Prediction of prognosis has a central role in the 
clinical management of all stages of the disease in particular for patients in severe 
phase. Prognostic scores based on clinical and biochemical parameters are introduced to 
support the clinicians in the prediction of survival and the need of liver transplantation. 
The most frequently used prognostic scores are the model for patients with end stage 
liver diseases (MELD) and the Child-Pugh scores.  
The MELD score is based on creatinine, bilirubin concentrations and international 
normalized ratio (INR), it predicts short term survival rates (3 months) and found 
application in the prioritization of patients in waiting list for transplantation2. The Child-
Pugh score assesses the long term prognosis basing on serum level of bilirubin and 
albumin, INR, the presence and severity of ascites and encephalopathy and allows to 
classify the chronic liver disease into three risk classes (A:5-6, B: 7-9, C: 10-15) 12. 
 
1.2.  Complication of liver cirrhosis 
1.2.1 Ascites and Hepatorenal Syndrome 
Ascites is the most common complication of cirrhosis. Approximately 15% of the 
patients with ascites will die in one year and 44% will die in five years. Ascites 
formation is a direct consequence of portal hypertension and of other events 
characterizing the disease.  In the advanced phases of cirrhosis the effort in maintenance 
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of arterial pressure supported by the activation of RAAS, SNS and anti-diuretic 
hormone (ADH) leads to retention of water and sodium. Unfortunately the prompt of 
fluid retention to refill dilated vascular bed is not efficient because the excessive 
production of lymph does not balance the return to systemic circulation and the 
consequence is a leakage of fluid in the abdominal cavity and formation of ascites13.  
In this setting a progressive impairment of renal function occurs, leading ultimately to a 
peculiar type of functional renal failure defined as hepatorenal syndrome (HRS). 
Indeed, the activation of neurohormonal vasoconstrictor, following the reduction of the 
effective arterial blood volume, lead to a vasoconstriction of the kidney, brain and 
peripheral vascular bed. While in a first phase renal vasodilator agents, such as 
prostaglandins, counterbalance this effect, in later phases the system fails and is 
unbalanced towards a vasoconstrictor tone. Thus a reduced glomerular filtration rate 
(GFR) and the development of HRS is the results of a severe reduction of renal blood 
flow8. HRS occurs as a late complication of advanced cirrhosis and may be triggered by 
infection, bleeding and paracentesis of a large volume of ascites without albumin 
infusion14.  
The diagnosis of HRS is based on criteria provided by the International Club of Ascites 
(IAC). The IAC defined HRS in type 1 and type 2, type 1 rapidly progresses and it’s 
characterized by doubling of the serum creatinine to a level > 2.5 mg/dL in almost two 
weeks14. The renal failure observed in type 2 HRS is moderate respect to type 1 (serum 
creatinine > 1.5 and up to 2.5 mg/dL), the evolution of its course is quite stable and it 
takes on from weeks to months14. While type 1 HRS, is normally generated by 
precipitating factors, HRS type 2 usually generates de novo in subjects with refractory 
ascites. 
1.2.2 Gastroesophageal varices 
In patients with cirrhosis, variceal bleeding is a frequent complication directly related to 
portal hypertension. Gastroesophageal varices are present in 30% of patients with 
compensated cirrhosis and 60% of patients with decompensated cirrhosis7. The 
formation and increase in size of varices are driven by local anatomical factors, an 
increased portal pressure and progressive development of neo-angiogenesis (particularly 
VEGF-dependent angiogenesis) in the splanchnic territory. The development of 
collaterals does not achieve a reduction of portal pressure because concomitant to this 
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event there is an increase in portal inflow deriving from splanchnic vascular bed and the 
intrahepatic resistance is higher than a normal liver to be sufficiently decompressed. 
Indeed, collateral system with its resistance contributes to the gradient of PH and the 
resulted variceal wall tension is the main cause of rupture and hemorrhage15. 
1.2.3 Hepatic encephalopathy  
Hepatic encephalopathy (HE) is a manifestation of decompensated cirrhosis, it occurs in 
50% of patients and it is a complication related to portal hypertension16. The increased 
hepatic resistance due to the progression of liver fibrosis and development of cirrhosis 
forces the portal blood to bypass the liver by flowing through portosystemic shunts. The 
skip of the portal blood to a collateral circulation implicates a decreased first-pass effect 
of orally administered drugs, reduced reticuloendothelial system and detoxification 
function that lead to the circulation of potential dangerous metabolites. Capillarization 
of sinusoids and intrahepatic shunts contribute to development of HE and they cause a 
reduced hepatocyte perfusion, a major determinant of liver failure. HE has a wide range 
of clinical manifestations, from impaired memory, diminished attention to confusion 
and coma. Many factors are implicated in its pathogenesis as the derangements in 
neurotransmitter pathways, cerebral blood flow modulation, and systemic inflammatory 
responses. Different studies have shown that ammonia has an important role in the 
pathogenesis of HE. This idea is based on an impaired capacity of the cirrhotic liver to 
convert ammonia in urea and glutamine. Indeed, the presence of shunts towards the 
systemic circulation promotes a wide spread of ammonia through arterial circulation17. 
Ammonia can reach the nervous central system and leads to multiple neurotoxic effects, 
including altering the transit of amino acids, water, and electrolytes across the neuronal 
membrane and propagating astrocyte swelling and cerebral edema7. More recently, 
several studies suggested that increased systemic inflammation significantly contribute 
to the pathogenesis of hepatic encephalopathy17. Indeed, level of serum inflammatory 
markers were found to be higher in patients with HE compared to those without HE 
regardless of the underlying severity of cirrhosis and ammonia level18. It was postulated 
that bacterial translocation, together with the impaired immune defense, hepatic 
hemodynamic changes and porto-sistemic shunts17, are the main driver of systemic 
inflammation in these patients.  
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The methods and biomarker selection to diagnose HE is a debating matter in particular 
for the identification of the Minimal Hepatic Encephalopathy, otherwise a series of 
specific test batteries to verify cognitive abilities have been evaluated in clinical studies 
but they showed to not have a good reliability and to be influenced by the population 
characteristic as education etc19.  
The severity of HE is graded basing on the West Haven classification20. This scale 
considers 4 stages that range from manifestations as a weak loss of memory to the most 
severe event represented by coma and not response to painful stimuli (Table 1). 
Classification of patients in different stages assumes a great importance for the clinics in 
particular  to evaluate the efficacy treatment administered. 
Table 1. The West-Haven classification, Z. Poh  and P. E. J. Chang  Int J Hepatol. 
2012.  
 
 
1.2.4 Bacterial infections  
Bacterial infections are one of the leading cause of death in cirrhotic patients and 
mortality reported is high as 19% 21 . Prevalence of infection is mainly related to the 
severity of liver disease. Risk factors for these patients are previous infection, 
gastrointestinal bleeding, history of alcohol abuse, medical procedures and ascites3. 
Cirrhotic patients are more exposed to bacterial infections compared to patients with 
other illnesses. First, they present alterations of bacterial flora and mucosal barrier, 
which concur, together with a major permeability of the latter, to a greater bacterial 
migration. Furthermore immunologic response is altered and partially impaired, thus 
favoring the progression and spread of infection 22. Once the infection has established, it 
can lead to complications such as severe inflammatory response, renal failure, 
encephalopathy and in worst case scenario multiorgan failure 22.  
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Spontaneous bacterial peritonitis (SBP) and urinary tract infections are the most 
frequent infections followed by pneumonia, bacteremia and finally skin and soft tissue 
infections23. Intestinal Gram-negative flora is the major cause of infections, several 
evidences suggests that bacterial translocation (BT) from gastrointestinal tract is the 
main mechanism which favors bacterial infection24. The onset of complications 
following BI underlines the need for vigilance and rigorous antimicrobial approach. The 
factors, predisposing cirrhotic patients to infections, are not well defined but several 
mechanisms are suggested. PH results in the formation of portosystemic anastomoses 
that, diverting blood from liver, determines an impairment of the hepatic detoxification 
function. The intra and extra-hepatic shunting of portal blood into the systemic 
circulation (hemodynamic derangement typical of decompensated cirrhosis) causes a 
progressive failure in detoxification of potentially harmful substances and consequently 
bacterial end-products received from the splanchnic circulation are released in the 
systemic circulation24. As previously outlined, bacterial translocation from 
gastrointestinal tract contributes to the onset of infections. It is due to an enhanced 
intestinal permeability, which results from several factors, among which oxidative 
damage of the intestinal wall, alteration in tight junctions of the intestinal epithelium, 
compromised Paneth cells defense and altered expression of anti-microbial peptides25. 
Depending from the etiology of cirrhosis, gut flora is subjected to changes of its own 
composition. These changes can lead to dysbiosis and a further overgrowth of harmful 
strains that increase the potential for infection26. In healthy individual BT can be easily 
controlled by the immune system, whereas for cirrhotic patients this event could 
comprise the survival. The reason is because cirrhosis can lead to a dysfunction of the 
immune system27 which consists in two main alterations: immunodeficiency related to a 
weaken response to pathogens and a systemic inflammation, as a result of persistent and 
inadequate activation of immune cells. 
The immunodeficiency consists in an impairment of innate and adaptive immune 
system (Figure 2) due to a series of factors: compromised immune mechanisms of the 
mesenteric lymph nodes, insufficient bacteriostatic and serum chemotactic capacity, a 
reduced neutrophil phagocytosis, a decreased number of circulating immune system 
cells and an hepatic reticuloendothelial dysfunction25. Importantly, a distinctive element 
that occurs at the same time of immunodeficiency is a systemic inflammation often 
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associated with marked immune activation, which correlates with the severity of liver 
disease and predicts survival in these patients28. This phenomenon initiates in advanced 
phase of liver cirrhosis, following BT which contributes to systemic inflammation10. 
PAMPs are recognized by PRRs on innate immune cells. The main recognition for 
bacteria and PAMPs occurs in the gut-associated lymphoid tissue (GALT) and 
mesenteric lymph nodes (MLN) and in the peripheral blood. Once the immune cells are 
activated in the GALT and MLN, they enter the peripheral blood and spread the 
inflammatory response systemically27.  
Cirrhotic patients frequently present systemic inflammatory response syndrome (SIRS), 
that is a complication related to the presence of a serial factors as bacterial translocation, 
impaired reticuloendothelial function and portosystemic shunts29. The result is an 
increased level of endotoxins in the systemic circulation, and a further activation of  
immune cells as monocytes that cause an excessive release of pro-inflammatory 
cytokines (interleukin-1, interleukin 6, TNF-α, interferon ϒ). In cirrhotic patients with 
SIRS, the onset of bacterial infection implicates a pronounced inflammatory response 
with elevated systemic concentrations of pyrogenic cytokines as IL-6 and TNF-α28.  
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Figure 2. Rearrangement of the hepatic and systemic immune system in liver cirrhosis. 
Albillos A et al, J Hepatol. 2014 Dec;61(6):1385-96. 
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2. Human Serum Albumin 
Human serum albumin (HSA) is the more abundant plasma protein which accounts for 
almost 50% of total plasma protein content 30. The first clinical application for HSA was 
during the second world war, when, thanks to its property of plasma expander, it was 
administered to severely burned patients injured during the Pearl Harbour attack. 
Subsequent advance in the knowledge of HSA properties, have led to a widening of the 
clinical indication for the use of HSA31. Indeed, HSA is provided of many other 
properties which are unrelated to the regulation of fluid compartmentalization and to the 
oncotic pressure, these properties are therefore defined as non-oncotic32. HSA is 
synthesized by hepatocytes, parenchymal cells of the liver, through the transcription of 
its gene located on the long arm of chromosome 4, for an amount of 10-15 gr. per day. 
Once synthesized, a part is stored in tissues (like muscle and skin) instead a consistent 
amount is released in the vascular space. Circulating albumin leaves plasma at a rate 
5%/h and returns in the vascular space at an equivalent rate through a lymphatic 
system33 HSA total half-life in an healthy male lasts from 12.7 to 18.2 days, while its 
circulatory half-life is much shorter, reaching approximately 16-18 hours30. HSA was 
synthesized following stimuli provided by hormonal factors, such as insulin, cortisol 
and growth hormone and changes in the plasma oncotic pressure, while pro-
inflammatory mediators, including cytokines, Interleukin-6 and Tumor Necrosis Factor-
α exert an inhibitory effect. 
2.1 Structure                                                                                                      
HSA is a small globular protein of 67 KDa, composed of 585 amino acids, with a 
negative charge (-15) at ph 7 due to an high content of acidic amino acids like lysine, 
aspartic acid, only one residue of tryptophan and few methionine residues34-35. The 
tertiary structure of HSA, as observed in x-ray crystallographic studies, is heart shaped, 
and is mostly composed of alpha helices. The molecule is organized in three 
homologous domains (I-II-III), each composed of two subdomains (A and B) with 4 and 
6 alpha helices respectively31 (Figure 3) .Thanks to its amino acid composition, HSA 
has a  structure enough flexible to be prone to bind several molecules, the presence of 
35 cysteines contribute to tertiary structure through the formation of 17 intra-molecular  
disulfide bridges. Only one cysteine at 34 position (Cys-34) has a free redox active thiol 
group (-SH) that can undergo to thiolation, nitrosylation, and reversible or irreversible 
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oxidation 30. Thanks to the presence of a free thiol group in its structure and the high 
content in the bloodstream, HSA represents the main circulating anti-oxidant system 36. 
 
 
Figure. 3  Crystal structure of human serum albumin,  subdomains (IA, IB, IIA, IIB, 
IIIA an IIIB), of the N and C-terminal, Sudlow’s sites I and II and the seven LCFA 
binding sites (FA1 to FA7) are shown. Purple spheres represent the heavy atoms of side 
chain of residue Cys-34. Arroyo V. et al, J Hepatol. 2014 Aug. ;61(2):396-407 
 
2.2 Functions 
2.2.1. Oncotic properties 
HSA is the main regulator of fluid distribution in the body compartments, indeed, it is 
responsible for 80% of the oncotic pressure of plasma (25–33 mmHg)37 .The osmotic 
pressure and the Gibbs-Donnan effect are the main mechanisms through which HSA 
influences the fluid distribution37. Indeed, approximately two thirds of the plasma 
oncotic pressure is represented by a simple osmotic pressure, due to HSA high plasma 
concentration. The other third arises from the Gibbs-Donnan effect, namely, the 
molecular negative net charge (at physiological pH) attracts positively charged 
molecules into the intravascular compartment38. Furthermore HSA binds the interstitial 
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matrix and sub endothelium reducing the permeability of these layers to large 
molecules, so that it may indirectly increase the intravascular oncotic pressure38.  
2.2.2 Non-oncotic properties 
Binding and transport. The HSA binding properties are related to its tertiary structure 
and multidomain organization. HSA binds molecules in order to increase their plasma 
solubility, to transport them to tissues and organs or to remove them when they are 
toxic31. HSA can transport and bind both exogenous and endogenous molecules. An 
example for endogenous compound is the group of long chain fatty acids (LCFA), that 
can circulate free or bound to HSA. HSA has 7 sites through which binds LCFAs with 
different affinity, Sudlow site I e II are included (Sudlow site are respectively in the 
subdomain IIa e IIIa of the molecule)30. The binding capacity of HSA is not limited 
only to LCFA but also to other endogenous molecules like eicosanoids, bile acids, 
unconjugated bilirubin, steroids, hematide, vitamin D and folates30. Regarding the 
interaction with exogenous molecules, several classes of drugs bind HSA, among which 
benzodiazepines, anticoagulants, non-steroidal anti-inflammatory drugs and 
antibiotics39. The binding of drugs to HSA is an important determinant for their efficacy 
and biodistribution. The main sites involved in drug interaction are Sudlow site 1 (for 
anticoagulants and anti-inflammatory drugs) and Sudlow site 2 ( for benzodiazepines 
and profens) but an higher drug concentration may involve other binding sites, whereas 
molecules as cisplatin, D-penicillamine, and N acetyl-cysteine bind to Cys 34 residue40 
(Fig. 4). The binding properties of albumin could be influenced by several physiological 
or pathological factors such as age, genetic factors, reversible or covalent binding of 
endogenous ligands and xenobiotics that may alter the functionality of the binding sites 
of the molecule39. 
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Figure 4. Crystal structure of human albumin showing the binding sites. The α-helical 
structures of the three domains (DI, DII, and DIII) are divided into subdomains (A and B) as 
indicated. DI (pink) contains the fatty acid binding site 1, the free cysteine (C34), and drug 
binding site 3. Fatty acid site 2 is located at the interface between DI and DII. The metal binding 
site is located between subdomain DIA and DIIA. DII (orange) contains the drug binding site 1 
(Sudlow’s site 1) as well as fatty acid sites 6 and 7. DIII (blue) contains fatty acid binding sites 
3 and 4, the drug binding site 2 (Sudlow’s site 2) in DIIIA, and the fatty acid biding site 5 in 
DIIIB. Sand KM et al. Front Immunol. 2015 Jan 26. 2015 Jan 26;5:682 
Anti-oxidant function. The anti-oxidant function awarded to HSA is mainly related to 
the capacity to bind metal ions at the N-terminal portion of the molecule and to the 
redox ability of the Cys-34 residue 30. Free metal ions could catalyze the formation of 
ROS (reactive oxygen species) and lead to Fenton reaction producing hydroxyl 
radicals30. The production of ROS has a dangerous effect on biomolecules leading to 
cell damage and HSA may limit this effect. Indeed, the N-terminal portion of HSA is 
provided by an indirect antioxidant activity. Thanks to its amino acid sequence (N-Asp-
Ala-His-Lys) it can bind metal ions as Cu (II), Co (II) e Ni (II) reducing their contribute 
to the generation of ROS and oxidative stress38. Beside the amino terminal portion of 
the protein, the Cys-34 residue has a direct anti-oxidant activity.  The presence of a free 
thiol group at Cys-34 residue leads albumin to be in plasma the main source of 
extracellular thiols (80% ) and a potent scavenger for ROS and reactive nitrogen species 
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(RNS)41. In healthy adults about 70-80 % of HSA exists predominantly in a reduced 
form with a free sulphydryl group at Cys-34 and preserved anti-oxidant ability, known 
as mercaptoalbumin (HMA). A small amount that consists in the 25 % of circulating 
protein is human nonmercaptalbumin1 (HNA1), in which Cys-34 is reversibly oxidized 
and it forms a disulfide bridge with small sulfhydryl groups like another cysteine, 
homocysteine or glutathione. A residual amount, representing approximately 5% of the 
total circulating HSA is human nonmercaptalbumin2 (HNA2), which is highly and 
irreversibly oxidized to sulphinic or sulphonic acid form leading to a permanent loss of 
its scavenger ability42. Oxidative modifications of the albumin molecule cause not only a 
loss of its anti-oxidant activity but interfere with the pharmacokinetics of the molecule 
itself, because the oxidized forms are degraded and removed faster.  
Immunomodulation and anti-inflammatory properties. Albumin carries out its 
immunomodulating function at different levels, through the regulation of 
neutrophil/endothelial cell interactions after shock and resuscitation, and influencing the 
intracellular glutathione levels (GSH) (an ubiquitous sulfhydryl thiol) which takes part 
into the cell protection mechanism against oxidant-mediated injury43. In vitro and in 
vivo studies showed that albumin does not directly interact with GSH by the Cys-34 
residue, but once internalized in the cellular compartment, it represents a source for 
precursors that lead to the de novo synthesis of GSH43. The consequent effect of the 
increase of intracellular GSH is the downregulation of the ubiquitous transcription 
factor nuclear factor-kappa B (NF-kB), following of a TNF α activation (oxidant-
sensitive transcription protein complex)43.  
Furthermore HSA can interact with pro-inflammatory substances and mediators of 
inflammation. Indeed, HSA can bind lipopolysaccharide (LPS), lipoteichoic acid, and 
peptidoglycans which are surface components of gram-negative and gram-positive 
bacteria that activate the innate immune system through the binding to Toll-like receptor 
4 (TLR4) thus inducing the transcription of pro inflammatory compounds31 . To activate 
the inflammatory response, LPS has to interact with several host proteins as LPS-
binding protein, CD14 and co-receptor MD-2, leading to cell activation. Recent findings 
suggest that Albumin can participate to the presentation of LPS to TLR4 44, otherwise 
the resulting immune activation is moderated respect to the endotoxin-CD14 
complexes45. Giving that circulating albumin is abundant and LPS-albumin complex has 
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a moderated effect on cell activation, indeed HSA could play a role in moderating the 
inflammatory response to bacterial infections45. Therefore, albumin could play a dual 
role either stimulating or moderating immune cells activation depending on 
pathophysiological conditions44-45. 
 
Anti-hemostatic effect. Nitric Oxide (NO) is a highly reactive molecule which causes 
vasodilatation in the vascular compartment33. Some studies showed that endogenous or 
exogenous NO interacts with Cys 34 residue of HSA through an electrophilic addition 
of nitrosium ion (NO+). Thanks to this process, NO can circulate in plasma as a S-
nitroso HSA adduct. The vasodilator properties of NO increase when it is transferred to 
low-molecular-weight thiols and consequently also its circulating availability33. S-
nitrosothiol adducts with respect to a free NO have a longer half-life, they can inhibit 
platelets through a cGMP-dependent mechanism and they possess endothelium-derived 
relaxing factor-like properties35.  
 
Endothelial stabilization. More than 50% of total body albumin is located into the 
extravascular compartment, and some studies on hydraulic conductivity carried out on 
monolayers of endothelial cells showed that HSA was able to influence vascular 
integrity 46. In vitro experiments demonstrated that increasing amount of HSA in 
luminal space causes a rise in barrier function and reduced vessel wall permeability 
thanks to the binding and to an increment of its number of interactions with 
extracellular matrix46.  
HSA beyond its influence on capillary permeability may also act on endothelial 
stabilization. This hypothesis is supported by ex-vivo studies 47and a randomized 
clinical trial 48on patients with spontaneous bacterial peritonitis (SBP) in which HSA 
administration effectively improved systemic hemodynamics and reduced endothelial 
dysfunction respect to other colloids thus strengthening the role of albumin as 
endothelial stabilizer. 
3. HSA in liver cirrhosis  
HSA is exclusively produced in the liver, therefore during chronic liver disease its 
circulating concentration is reduced leading to a condition of hypoalbuminemia49. A 
reduced concentration of HSA results in part from a decreased synthesis related to 
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parenchymal cells loss and in part from vascular abnormalities which occurs during 
cirrhosis 50. Namely, the retention of renal sodium and water following splanchnic 
arterial vasodilatation, lead to plasma volume expansion and to a further dilution of the 
extracellular fluid protein content including that of HSA 50. In the more severe phases of 
disease the increase in the trans-capillary escape rate of HSA further contributes to the 
reduction of its circulating level50. Thus, in the field of hepatology, the administration of 
commercial HSA preparations is now indicated for the treatment or prevention of severe 
complications of cirrhosis 51. In lights of new findings about HSA properties, benefits 
after its administration have been ascribable not only to its plasma volume expander 
ability but also to its non-oncotic properties51. 
3.1 Clinical indications for the use of HSA in patients with cirrhosis 
Clinical use of HSA for cirrhosis dates back to the forties years, when the main 
indication for albumin infusion was ascites because there was the idea that 
hypoalbuminemia could be the main cause for ascites formation50. In the years between 
1940-1960 several studies were carried out to evaluate the effects of HSA 
administration on the management of ascites52. In these studies the administration of 
HSA was aimed to reduce ascites formation by increasing microvascular oncotic 
pressure and stabilizing circulatory and renal function through the expansion of total 
blood volume52. The observed results from these studies showed an increase of serum 
albumin levels and normalization of the oncotic pressure, however the treatment did not 
lead to a considerable reduction in ascites formation, even if the therapy lasted for 
prolonged periods53. Although these studies failed to reduce ascites formation, they 
demonstrated that a reduction in oncotic pressure did not play a role in the pathogenesis 
of ascites formation.  
Actually the clinical indications for albumin administration in patients with cirrhosis are 
the prevention of circulatory dysfunction induced by paracentesis of large volume of 
ascites, the treatment of HRS and prevention of renal complications due to spontaneous 
bacterial peritonitis51. Otherwise, clinical studies are currently evaluating the 
appropriateness of the use of HSA for the improvement of patients prognosis and the 
treatment or prevention of other complications as bacterial infections, hepatic 
encephalopathy and septic shock54.   
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3.1.1 Prevention of post-paracentesis circulatory dysfunction 
The progresses in the knowledge of liver cirrhosis physiopathology showed that 
cardiovascular abnormalities were involved more than hypoalbuminemia in the 
development of ascites 55. Therefore, in the eighty years, commercial HSA preparations 
found application in patients undergone paracentesis of large volume (LVP, more than 
5L) of ascites to prevent post-paracentesis circulatory dysfunction (PPCD). This 
nosocomial procedure represents the first line treatment for refractory ascites and 
consists in the removal of large amount of ascitic fluid from the peritoneal cavity55. 
LVP may lead to circulatory dysfunction (CD), deriving from the activation of the 
renin-angiotensin system which contributes to an exacerbation of the arteriolar 
vasodilatation associated to an insufficient cardiac response 56. Normally CD does not 
revert spontaneously and is associated to an increased risk of mortality and acute renal 
failure56. Albumin infusion given at the same time of LVP or at the end of the procedure 
has shown to be effective in the prevention of CD57. The reason of this positive effect 
consists in the ability of albumin to be a plasma volume expander with a longer 
persistence in the vascular compartment (21 days of half-life in cirrhotic patients) 
respect to other artificial colloids58. Its prolonged half-life favors the maintenance of 
circulatory homeostasis, that is severely compromised in these patients. Clinical trials 
further confirmed that albumin administration compared to other fluid volume 
expanders is able to reduce  the development of complications related to PPCD as 
hyponatremia, renal failure and risk of mortality59. A better performance of HSA respect 
to other known colloids lets to hypothesize the beneficial effects of HSA extend beyond 
its oncotic function.  
3.1.2 Treatment of Hepatorenal syndrome 
Hepatorenal syndrome (HRS), as explained previously, is a severe and progressive 
functional renal failure occurring in patients with cirrhosis and ascites characterized by 
splanchnic arterial vasodilatation in association with cardiac dysfunction8. A worsening 
of circulatory dysfunction coupled to activation of compensatory mechanisms as RAAS 
and sympathetic nervous system cause renal hypoperfusion and organ dysfunction. 
Even if the HRS are distinguished in type 1 and type 28, the main investigations and 
collected information regard type 1 HRS. Recent data showed that the combination 
albumin-vasoconstrictors resulted the most effective treatment with respect to the use of 
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vasoconstrictors alone60. The reason of the effectiveness of this combination resides in 
the fact that albumin increases renal blood flow, glomerular filtration rate and decrease 
serum creatinine level, on the other hand vasoconstrictors act at the splanchnic vascular 
bed level increasing vascular resistances and consequently the mean arterial pressure 
and renal perfusion61.The most studied vasoconstrictor is terlipressin, that, administered 
in association with HSA, is effective in the improvement of renal function and in the 
full reversion of type 1 HRS in 40-50% of patients 57. Also in decompensated cirrhotic 
patients affected by acute kidney injury (AKI) albumin infusions showed to improve 
renal blood flow62. The assessment in these patients of markers related to endothelial 
dysfunction, oxidative stress and endotoxemia revealed that the beneficial effect of HSA 
infusion is mainly related to the endothelial stabilization and to the reduction of 
oxidative stress more than to its oncotic function62. 
3.1.3 Prevention of renal complications related to SBP 
Patients affected by SBP show an increased level of cytokines and vasodilator factors in 
plasma and ascitic fluid63. These compounds lead to changes in effective arterial blood 
volume that further contribute to the onset of renal complications 63. HSA 
administration achieved an improvement of hemodynamics in patients with SBP, this 
effect was showed to be not only related to oncotic function but also to the 
immunomodulation, antioxidant and endothelial stabilization capacity of the protein25. 
A clinical trial, in which the effect of HSA infusion was compared with that of another 
colloid, demonstrated a rise of systemic vascular resistances after HSA administration, 
and a fall of the circulating levels of von Willebrand-related antigen, factor VIII, and 
nitric oxide metabolites, indicating that HSA can interfere with the endothelial 
activation54. Furthermore, other clinical studies showed that the combination of HSA 
and antibiotics in patients with SBP could better reduce the incidence of renal failure 
and the mortality rate64. The beneficial additional effect of HSA administration to the 
antimicrobial therapy was supported by another trial where the combination of 
cefotaxime and HSA with respect to the antibiotic alone resulted in an almost avoided 
occurrence of renal impairment and lowered mortality both during hospitalization and 
after 3-months from the discharge24. Therefore, the achieved benefits after HSA 
administration clearly appear to be not only related to its oncotic function but also to 
many other physiological non oncotic functions. 
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4. Post-transcriptional modifications of HSA during cirrhosis 
Pathological conditions as sepsis, diabetes, chronic renal failure and cancer are 
characterized by production or accumulation of endogenous ligands or substances that 
can bind and/or oxidize HSA leading to changes in its structure and functionalities. 
Liver cirrhosis takes part to the list of disease able to induce these alterations32. Indeed, 
several studies, through the analysis of plasma HSA from cirrhotic patients, confirmed 
the idea that liver cirrhosis could induce changes in albumin non-oncotic functions. 
Watanabe et al 65 showed that the percentage of oxidized albumin increased with the 
progression of cirrhosis. Namely, oxidized albumin was found to progressively increase 
over the three different Child Pugh classes in parallel to a reduction of the total serum 
albumin concentration (Figure 5)65. 
 
 
Figure 5.Oxidized albumin percentage (black bars) and serum albumin level (white 
bars) measured  through an immunoassay in healthy controls and cirrhotic patients. 
Watanabe et al Nutrition. 2004 Apr. ;20(4):351-7. 
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In the same study an increased percentage of glycosylated albumin in cirrhotic patients 
was also demonstrated65. Glycation is another post-transcriptional modification that 
occurs through a non enzymatic reaction and involves glucose and/or other sugars that 
attach free amino group of albumin66. This modification may be somewhat expected in 
patients with liver cirrhosis because one third of patients suffer of diabetes67. 
A further characterization of oxidative modification to the HSA molecule during 
cirrhosis was performed by Oettl et al. The authors observed that in cirrhotic patients 
there is a significant trend towards the reversible and irreversible oxidation of the Cys-
34 residue of the HSA molecule as revealed by the plasma HMA, HNA1 and HNA2 
levels68. Such result was confirmed in subsequent studies performed in larger cohort of 
cirrhotic patients in which an higher plasma HNA2 level was observed in 
decompensated cirrhosis. In the same study the HNA2 level significantly correlated 
with the severity of cirrhosis and was a good predictor of short and medium term 
mortality69. 
Beside oxidative modifications at the Cys-34 level, post-transcriptional changes can 
occur also in other sites of the HSA molecule. In the early 1990, Ischemia modified 
albumin (IMA) was described for the first time70. At the beginning, this protein variant 
seemed to be produced only under myocardial ischemia condition, thereafter several 
studies assessed its presence in other pathological conditions as liver cirrhosis, acute 
infection and advanced cancer70. The N-terminal portion of HSA displays an indirect 
anti-oxidant activity being able to bind metal ions71. Otherwise the site is susceptible to 
biochemical degradation and is less stable under environmental changes, so it could be 
affected by hypoxia, acidosis and free radicals70. Indeed IMA consists in an isoform 
with altered amino terminal site which causes a transient loss of scavenging ability  
leading metals to circulate free and participate into reactions that produce detrimental 
metabolites for patients30.  
Jalan et al 72 have measured plasmatic levels of IMA in patients with different grades of 
cirrhosis severity. In this study the authors found that the ratio IMA/serum albumin 
concentration (IMAR) increased with the severity of cirrhosis, a result that mirrored the 
increase of oxidative stress which characterizes the more advanced phases of the 
disease. IMAR was also found to be an eligible biomarker to predict mortality and to 
determine survival in patients with acute decompensation of cirrhosis72.  
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During the last ten years, new proteomic techniques as High-performance liquid 
chromatography (HPLC) coupled to mass spectrometry (ESI-TOF MS) allowed the 
better identification and characterization of HSA structural alterations73. This method 
was initially used from Bar-Or and colleagues74 to evaluate post-transcriptional changes 
of HSA in different commercial preparations of albumin and to compare them to that 
found in circulating HSA from healthy volunteers. Cysteinylation and nitrosylation of  
the cysteine 34 residue were described together with a S-nitrosoalbumin isoform74. It’s 
well known that NO bound to albumin has a prolonged half-life moreover experimental 
studies conferred to this isoform anti-inflammatory action as in case of lung acute injury 
due to endotoxemia75 and a protective effect on liver cells in animal models of 
ischemia/reperfusion injury76. Otherwise, nitrosylation of cys34 causes a decrease in 
allosterical affinity to copper ions and to other molecules30. An additional modifications 
described by Bar-or and colleagues was the truncation at the N-terminal portion of 
HSA74. This change consists in a loss of the last two aminoacidic residue (Asp-Ala) 
from the N-terminal portion of HSA, the site of the molecule  involved in the binding of 
transition metals ions71. The truncation and further loss of this site means a permanent 
loss of HSA scavenging ability.  
More recently, our group revisited the method initially described by Bar-Or and 
colleagues in order to render this approach reliable to be applied in clinics for the 
assessment of circulating albumin microheterogeneity73. With this approach several 
HSA isoforms were identified in plasma samples from healthy voluntaries and from a 
small series of cirrhotic patients. Namely, isoforms characterized by reversible 
(HSA+CYS) or irreversible (HSA+SO2H) oxidation of the Cys-34 residue, truncation of 
the N-terminal (HSA-DA) and C-terminal (HSA-L) portion of the molecule, 
glycosylation (HSA+GLYC), and the co-occurrence of such structural alterations 
(HSA+CYS-DA: N-terminal truncated and reversibly oxidized; HSA+CYS+GLYC: 
reversibly oxidized and glycosylated) have been identified73 (Figure 6).
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Figure 6 .Deconvoluted ESI-MS spectra of HSA from (a) an healthy volunteer and (b) 
cirrhotic patient plasma. A fast and validated mass spectrometry method for the 
evaluation of human serum albumin structural modifications in the clinical field. 
 Naldi M et al. Eur J Mass Spectrom (Chichester, Eng), 2013. 
 
These results were congruent with those obtained from Bar-or74 and the method was 
tested for inter- and intra- day reproducibility. The validation of this method gave the 
opportunity to extend the analysis of albumin structural alterations in patients in order to 
provide additional information about the structural integrity of circulating HSA. In this 
view the evaluation of HSA structural alteration in a large cohort of cirrhotic patients 
will provide the opportunity to match clinical observations to information about 
albumin microheterogeneity thus unraveling the potential clinical relevance of such 
structural alterations. 
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4.1 Other post-transcriptional changes of HSA  
Additional structural modifications of the HSA molecule were described in clinical 
settings other than cirrhosis. Indeed, the formation of albumin homodimers has been 
proposed as an oxidative structural modification that occurs to the HSA molecule in-
vivo77. The formation of albumin disulfide dimers was already reported in dialyzed 
human plasma following exposure to peroxynitrite, additionally the concentration of 
albumin dimers was significantly increased in the circulating blood of patients with 
chronic renal disease, compared to age-matched healthy subjects 77 (figure 7). The 
dimerization process seems to involve a disulfide bonds at the Cys-34 residue thus 
contributing to a further reduction of the non-oncotic activity of the circulating albumin 
pool by impairing the antioxidant properties of the protein78. 
 
 
 
 
Figure 7. Detection of albumin dimer in plasma from healthy subjects (lane 1-3) and 
hemodialysed patients (4-6) by western blot.  Monomeric albumin and albumin dimers 
are indicated by black arrows. Formation of albumin dimers induced by exposure to 
peroxides in human plasma: a possible biomarker for oxidative stress. Ogasawara et al, 
K. Biochem. Biophys. Res. Commun, 2006. 340, 353–8.  
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AIMS OF THE STUDY 
 
The main aim of this project was studying in a large cohort of cirrhotic patients, 
admitted to the hepatological units of Sant’Orsola-Malpighi Hospital (Bologna, Italy)  
for the onset of a complication of the disease, the functional and structural alterations of 
Human serum albumin. 
First, by using an innovative technological approach based on mass spectrometry we 
will  identify and characterize, structural modifications to the HSA and the sites of the 
molecule involved. Once the number of different existing isoforms and the extension of 
alterations will be assessed, we will analyze their association with clinical 
complications and severity of the disease and, if any, their prognostic role. 
Basing on the hypothesis that oxidative stress, as it develops during cirrhosis, could be 
the main driver of HSA structural alteration, further experiment will be performed in 
vitro  to assess the relationship between a pro-oxidant environment and modifications of 
albumin structure. 
An additional aim of the study is the evaluation of functional alterations of HSA during 
cirrhosis by analyzing the N-terminal portion of the molecule, which carries an indirect 
antioxidant activity, in the same cohort of patients. Then we will evaluate if such 
alteration is related to the severity of disease and/or associated to specific 
complications. Finally, additional evaluations will be performed in rats with 
experimental cirrhosis in order to further characterize the relationship between acute 
event, such as bacterial infection,  and the functional alteration of the N-terminal portion 
of the albumin molecule. 
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MATERIALS AND METHODS 
 
1. Patients 
From July 2011 to March 2012, all patients admitted to the hepatological units of the S. 
Orsola-Malpighi university hospital for the onset of a clinical complication of cirrhosis 
complication were screened for study enrollment. 
Exclusion criteria were age: under 18 years, admission for a scheduled procedure, 
hepatocellular carcinoma (HCC) exceeding the Milan criteria, heart and respiratory 
failure, organic renal diseases, onco-hematologic disorders, protein-losing syndromes, 
albumin infusion in the previous month, and ongoing immunosuppressive treatment. A 
group of patients with a stable cirrhosis attending the outpatient clinics for scheduled 
surveillance and age and sex comparable healthy voluntaries to be used as reference 
population were also evaluated. Informed written consent was provided by patients and 
healthy controls, and the study protocol approved by the local ethical committee 
according to the 1975 Declaration of Helsinki. 
2. Study design and definition 
At the time of the inclusion in the study for each subject peripheral blood sample was 
withdrawn from the brachial vein into pyrogen-free tubes (Vacutainer EDTA and 
Heparin tubes; Becton Dickinson Italia, Milan, Italy), and immediately centrifuged at 
3,000g for 10 minutes. Plasma samples were than aliquoted into cryotubes (Corning 
Inc., Corning BV, Amsterdam, The Netherlands) and stored at -80°C until analysis. 
For both hospitalized patients and outpatients, a routinely biochemical evaluation, 
including tests of liver and renal function, and coagulation parameters were performed. 
Prognostic scores as Model of End-stage Liver Disease (MELD)79, Child-Pugh80 and 
Chronic Liver Failure-Sequential Organ Failure Assessment (CLIF-SOFA)81 were 
calculated when appropriate to assess the disease severity.  
The diagnosis of cirrhosis was based on clinical, biochemical, ultrasound (US) or 
endoscopic features.  
Evaluation of complication was performed as follows: ascites through ultrasound 
examination; hepatic encephalopathy was graded according to the West-Haven 
classification82; renal impairment was defined as a serum creatinine greater than 1.5 
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mg/dL; and upper gastrointestinal bleeding was confirmed by endoscopy. Diabetes was 
diagnosed according to the American Diabetes Association guidelines83. 
The occurrence of Bacterial infection was evaluated according to the following criteria:  
• spontaneous bacterial peritonitis: polymorphonuclear cell count in ascites 
>250/mm3;  
• urinary infection: positive urine culture or >10 leukocytes per high-power field 
in urine associated with suggestive clinical symptoms and signs of bacterial 
infection; 
• pneumonia: presence of new infiltrates on chest X-ray; 
• skin/soft tissue infection: physical examination findings among which swelling, 
erythema, heat and tenderness of the skin;  
• spontaneous bacteremia: positive blood cultures and no evident cause of 
bacteremia;  
• other infections (diverticulitis, cholecystitis, and meningoencephalitis): 
according to specific findings at the laboratory, microbiological, and imaging 
assessment.  
Hospitalized patients were followed-up until discharge and up to one year for survival. 
 
 
3. Evaluation of HSA structural alterations 
3.1 Identification and relative quantification of HSA monomeric isoforms 
3.1.1 Sample preparation 
EDTA-treated serum samples were diluted 1:10 with water/acetonitrile (98/2; v/v) 
mixture and filtered with an 0.22-µm filter (Merck KGaA, Darmstadt, Germany). A 
further dilution (1:100) with the same mixture was then performed before each injection 
in LC-MS system. In order to obtain a certain identification of HSA isoforms, plasma 
sample from CH patient containing approximately 95 µg of HSA was treated with DTT 
10 mM in ammonium bicarbonate buffer (100 mM, pH 8.0) for 30 min at 56°C to 
reduce disulfides. After cooling, sample was treated with iodoacetamide 55 mM in 
ammonium bicarbonate buffer (100 mM, pH 8.0) at room temperature for 45 min in the 
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dark to alkylate cysteine residues. The plasma sample was finally digested using trypsin 
overnight at 37°.  
In a different experiment setting, focused on the identification of Cys34 alterations, 
serum sample containing approximately 3.5 µg of HSA was directly digested overnight 
with trypsin. All the tryptic digested were analysed by an LC-ESI/MSMS approach. 
 
3.1.2 HSA LC/ESI-MS analysis  
HSA LC-MS characterization was performed adopting a validated and optimized 
protocol previously published from our group73. A nano-LC (liquid 
chromatography)/nano-ESI/Q-TOF (quadruple time-of-flight) analysis was performed 
by using a nano-LC Agilent 1100 Series (Agilent,Walbronn, Germany) interfaced with 
a Q-TOF hybrid analyzer (Q-TOF Micro; Micromass, Manchester, UK) with a nano-Z-
spray ion source. Reversed-phase chromatographic separations of HSA from other 
serum proteins was performed on a C8 (50 mm x 75 µm; 3.5 µm) column, using an 
elution gradient from A (water: acetonitrile: FA [99:1:0.1] [v/v/v] / B (acetonitrile: 
water: FA [98:2:0.1] [v/v/v] 85/15 [v/v]) to A/B 20/80 (v/v), in 20 minutes, at a flow 
rate of 0.5 µL/min; the system was equipped with an auto-sampler, and the injection 
volume was 1 µL. The column was equilibrated with the mobile-phase composition of 
the starting conditions for 10 minutes before the next injection. The mass spectrometric 
analysis was performed by setting the source temperature at 100 ºC, the capillary 
voltage at 3.5 kV, and the cone voltage at 42V. The scan time was set at 2.4 seconds 
and the interscan time at 0.1 sec. Mass chromatograms were recorded in total ion 
current (TIC) mode in the mass range 600-2,500 m/z (mass/charge). To characterize 
HSA isoforms by molecular-weight determination, multicharged mass spectrum was 
acquired on the chromatographic peak apex identified as HSA. Deconvoluted ESI mass 
spectrum of HSA was obtained by using MassLynx 4.1 software (Waters Corporation, 
Milford, MA). The peak averaged mass spectra were reconstructed and the mass of the 
HSA isoforms derived. 
For each isoform the absolute intensity was computed and then the relative abundance 
of each isoform was determined according to the following formula: 
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3.1.3 HSA isoforms identification by  2D-LC-ESI-MSMS analyses 
The first dimension RP-LC separation was performed on Agilent 1200  HPLC System 
(Walbronn, Germany) by using a Zorbax Extend-C18 RP column (3.5 µm, 80 Å, 100 
mm × 2.1 mm i.d.). Mobile phases A [water/acetonitrile (98/2) (v/v), adjusted pH to 
10.0 using ammonium hydroxide] and B [acetonitrile/water (98/2) (v/v), adjusted pH to 
10.0 using ammonium hydroxide] were used to develop a gradient from 2 to 70% of 
mobile phase B in 20 min. Tryptic peptides (~30 µg) were separated at an eluent flow 
rate of 0.3 mL/min and monitored at 214 nm. Eluent was collected every 2 minutes. The 
samples were dried under vacuum and reconstituted in 30 µL of 0.1% (v/v) FA, 2% 
(v/v) acetonitrile in water for subsequent analyses. Second dimension separation was 
carried out by using a nano-LC Agilent 1100 Series (Walbronn, Germany). Analyses 
were performed on a C18 (150 mm x 75 µm; 3.5 µm) column. Mobile phases A [water: 
acetonitrile: FA (99:1:0.1) (v/v)] and B [acetonitrile: water: FA (98:2:0.1) (v/v)] were 
used to develop a gradient from 5 to 55 of mobile phase B in 70 min.  
Mass spectrometry analyses were performed on the Q-TOF (Micromass, Manchester, 
UK) with nano-Z-spray ion source. The ESI-QToF source temperature was set at 
110°C, the capillary voltage at 3.5 kV, and the cone voltage at 40 V.  
Fragment ion spectra obtained from LC-ESI-MS/MS analyses were processed using 
Mascot Distiller (Matrix Science, London, UK) and the data were analyzed by searching 
the human SWISSPROT database (www.uniprot.org). Oxidation to sulfonic and sulfinic 
acid, nitrosylation and cysteinylation at Cys (amino acid) residues, glycosylation at Ser, 
Asp and Lys residues and Met oxidation were included as variable modification while 
carbamidomethylation, as fixed modification on Cys residues, were included when 
samples were treated with DTT and iodoacetamide. 
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3.2 Identification and characterization of HSA dimeric form 
3.2.1 Identification of HSA dimeric form in plasma samples by Western Blot analysis 
In order evaluate the HSA dimerization occurs in patients with cirrhosis, plasma 
samples from  three cirrhotic patients and three healthy subjects were subjected to 
native protein electrophoresis and western blot analyses. Sample were diluted 1:2 in 
double distilled water (DDW) and filtered through 0.22-µm filters (Millex GP). Total 
protein content of the sample was assessed  through the Lowry method and the protein 
concentration was normalized; 168 µg of total plasma proteins of every sample were 
mixed with Laemmli Buffer and loaded on a native 8% polyacrylamide gel. After 
separation proteins were blotted on a PVDF membrane (Millipore) and incubated 
overnight with rabbit anti-human albumin (1:8000; Dako). After incubation with 
horseradish peroxidase-conjugated anti-rabbit antibody, the immune complexes were 
detected by enhanced chemiluminescence with an ECL kit (Westar C, Cyanagen). The 
signal was acquired by exposing membranes on a ChemiDoc XRS System (Biorad). 
3.2.2 Identification of HSA dimers by MALDI-ToF analysis  
Serum sample was diluted (1:10) with water and ultrafiltrated at 4°C 4000 rpm for 1h 
[Amicon Ultra with 3 K cut-off (Millipore)], after that a washing step was performed. 
Once concentrated and purified sample was subjected to MALDI-ToF MS using a 
Voyager DE Pro (Applied Biosystems, Foster City, CA) equipped with a pulsed N2 
laser operating at 337 nm. Positive ion spectra were acquired in linear mode over an m/z 
range from 50,000-200,000 using a 25,000 V accelerating voltage, a 22,000-V grid 
voltage, and a delay extraction time of 150 ns. The spectrum for each spot was obtained 
by averaging the result of 120 laser shots. External mass calibration was performed 
using the single- and double-charged ions of bovine serum albumin (Sigma–Aldrich). 
The analysis was performed by spotting on the target plate 1 µL of the sample mixed 
with an equal volume of the matrix solution, 30 mg/mL sinapinic acid in 1:1 (v/v) 
ACN/H2O containing 0.1% (v/v) trifluoroacetic acid (TFA). 
3.2.3 Assessment of the site involved in the dimerization process. 
A serum sample containing approximately 95 µg of HSA was diluted 1:10 with 10 mM 
ammonium bicarbonate, pH 8.0 and digested using trypsin at a mass ratio of 1:50 
enzyme/protein overnight at 37 °C. The hydrolysis was stopped by addition of 1% 
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formic acid (FA) and the sample was analyzed by a 2D-LC-ESI/MSMS approach 
described in section 3.1.3. 
3.2.4 Role of oxidative stress in the dimer formation 
Serum sample from an healthy volunteer was incubated at 37°C in the presence of t-
butyl hydro peroxide (t-BuOOH). 
Time dependent experiments were performed incubating serum (99 µL) with t-BuOOH 
(1 µL) to reach the oxidative agent final concentration of 0.2 and 2 mM. The oxidation 
process was monitored at 0.5, 1, 2, 3, 6, 24 and 48 h. For the dose dependent studies 
serum (99 µL) was incubated for 24 h with t-BuOOH (1 µL) to reach the oxidative 
agent final concentration 0, 0.05, 0.075, 0.1, 0.2, 1 and 5 mM. The incubation mixture 
was diluted (1:100) with water at fixed times and 15 µL were analyzed with the LC-
ESI-MS approach. 
3.2.5 HSA Dimeric form analysis by LC-ESI-MS 
Serum sample preparation was performed as described in section 3.1.1 HSA dimeric 
form LC-ESI-MS analysis was performed as described in section 3.1.2. The dimeric 
HSA detection was obtained deconvoluting the baseline-subtracted spectrum (m/z 
1084–1534) acquired on HSA peak apex in the mass range 61,500–138,000 Da. 
The isoforms relative percentage abundance was calculated by dividing the isoform 
intensity obtained from the deconvoluted and baseline-subtracted spectrum by the sum 
of all isoform intensities and multiplying them by 100. Data were analyzed by Excel. 
For the oxidative experiments, described in section 3.2.4, the relative abundance of each 
dimeric isoform was expressed in percentage and calculated following this formula:         
 
		
		 + 		
	100 
 
The HSA dimer area consists in the sum of all dimeric HSA isoforms while the HSA 
monomer area intends the sum of all the monomeric HSA isoforms. 
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4. Evaluation of HSA functional alterations 
Alterations of the metal binding activity of the N-terminal portion of HSA were 
evaluated through the measurement of the circulating level of Ischemia modified 
Albumin ( IMA).  
4.1 Evaluation of IMA and IMAR in human plasma samples 
IMA levels were measured through the Albumin Cobalt binding test (ACB)78 in 
heparinized plasma samples. This colorimetric assay allow to quantify the ability of 
HSA to chelate cobalt. Briefly 200µl of plasma samples were incubated with 0.1% 
cobalt chloride for 10 minutes. Afterward dithiothreitol (1.5 g/L,2 min) was added and 
the mixture diluted in saline solution prior to measurement at 470 nm in a 
spectrophotometer (BioMate3; Thermo Spectronic). The IMA level in each samples was 
expressed as relative absorbance unit (ABSU), while  the IMA to albumin ratio (IMAr) 
was calculated by dividing the IMA value for total serum albumin concentration as 
measured by standard commercial kit54. 
4.2 Experimental animal studies 
The relationship between bacterial infections and plasma IMA levels was also evaluated 
in experimental cirrhosis. Briefly, six male Wistar rats (Charles River Laboratories), 
weighing 175–200 g, were housed in a temperature (22–24°C) and moisture (40–70%) 
controlled room with a 12-h light-dark cycle. Cirrhosis induction was carried out 
through CCl4 inhalation following a validated protocol79, at the same time phenobarbital 
(0.3 g/L in drinking water) was administered to shorten the time required to induce 
cirrhosis. After 14–18 weeks of CCl4 administration, all rats developed ascites as 
confirmed by ultrasound examination. Cirrhotic rats and six age and sex matched 
healthy rats received a single intravenous injection through the tail vein of 
lipopolysaccharide (10 mg/kg LPS, Escherichia coli 0127-B8; Sigma Co). After 2 and 
6h from LPS administration, 0.5 ml of blood was withdrawn from the tail vein and 
plasma IMA was evaluated as above described. All animal experiments were conducted 
according to the guidelines for the care and use of laboratory animals and were 
approved by the ethical committee of our Institution. 
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5. Statistical analysis  
All continuous variables were expressed as mean and standard deviation, while 
categorical data were reported as frequencies [n(%)].  Comparisons between categorical 
variables were made by means of the chi-square test while differences in HSA isoform 
relative abundance between control subjects, outpatients, and  hospitalized patients with 
cirrhosis were assessed by one-way analysis of variance (ANOVA) with Bonferroni’s 
correction for multiple comparisons. The comparison of IMA and IMAr levels in 
healthy controls and cirrhotic patients was made by means of Student’s t-test. The 
relationship between relative abundance of HSA isoforms, IMA, IMAr and MELD and 
Child-Pugh scores was evaluated by the Spearman’s rho correlation analysis.  
The association between HSA isoforms relative amount, IMA, IMAr, age, MELD and 
Child-Pugh scores, and specific clinical complication (ascites, renal impairment, and 
bacterial infection) in hospitalized patients was assessed by means of Student’s t-test.  
Multivariate analysis were performed with logistic regression with Wald’s backward 
method, where the dependent variable was the presence of a specific complication. Only 
variables significantly associated to the specific outcome (p<0.005) at univariate 
analysis were entered in the multivariate analysis. 
Survival analysis was performed by means of univariate Cox regression model. For 
each parameters found to be significantly associated to 1-year survival the best cut-off 
was calculated through the Receiver Operating Characteristics (ROC) curve analysis. 
Then survival curves were plotted according the Kaplan Meier method, while the 
survival rates of different groups were compared by means of Log Rank test. 
 All tests were two sided, and values of p less than 0.05 were considered statistically 
significant. All analyses were performed using the Statistical Package for Social 
Sciences (SPSS) version 20.0 (IBM Corp., Armonk, NY). 
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RESULTS 
 
1 Patients 
One hundred thirty-three cirrhotic patients (59 ± 11 years; 64% males) admitted to the 
hepatological unit of the S. Orsola-Malpighi University Hospital for the onset of 
complications of cirrhosis were consecutively enrolled. Thirty-five patients with stable 
cirrhosis attending to the outpatients clinic (56 ± 13, 71% males) and forty-four healthy 
volunteers (57 ± 9 years; 58% males) were also recruited. Data regarding etiology of 
cirrhosis, causes of hospitalization, biochemical parameters, MELD and Child-Pugh 
scores of patients were reported in Table 2. The more frequent complications registered 
at admission were ascites (66 pts), bacterial infection (41 pts) and renal impairment with 
creatinine>1.5 mg/dL (33pts). Forty-seven (35%) patients with decompensated cirrhosis 
and 9 (36%) outpatients had type II diabetes mellitus while 14 (10%) patients with 
decompensated cirrhosis and 6 (21%) outpatients had HCC meeting the Milan criteria. 
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Table 2. Clinical characteristics of hospitalized patients and outpatients with cirrhosis 
enrolled in the study.  
 Data are presented as mean ± standard deviation or frequencies (%) 1Renal impairment 
= serum creatinine > 1.5 mg/dL 2Prothrombin time international normalized ratio. 
 
 
Hospitalized patients 
N=133 
Outpatients 
N=35 
Etiology of cirrhosis   
 Viral  74 (55%) 19(54) 
 Alcohol  29 (22%) 7 (20) 
 Other  30 (23%) 9 (26) 
Complication at hospital admission   
 Ascites  66 (50%) - 
 Bacterial infection  41 (31%) - 
 Renal impairment1 33 (25%) - 
 Encephalopathy grade III-IV  13 (10%) - 
 Variceal Bleeding  9 (7%) - 
 HCC meeting the Milan criteria  14 (10%) - 
Biochemical parameters   
 Serum bilirubin (mg/dL) 4.4±5.8   2.1±3.3 
 Serum albumin (g/dL) 3.3±0.7   3.5±0.6 
 Serum creatinine (mg/dL) 1.2±0.7   1.2±0.9 
 Serum sodium (mmol/L) 137±4   138±4 
 INR2 1.56±0.45   1.25±0.19 
Prognostic scores   
 Child-Pugh class (A/B/C) 27/77/29 
(20/58/22) 
19/12/4 
(54/34/12) 
 Child-Pugh score 8±2   7±2 
 MELD score 17±7   12±5 
Comorbidities   
 Diabetes 
Hcc meeting the Milan criteria                                              
47 (35%) 
14 (10%) 
9(26%) 
6(21%) 
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2 Structural alterations to the HSA molecule  
2.1 Monomeric HSA isoforms in healthy subjects and hospitalized patients with 
cirrhosis 
2.1.1 Monomeric HSA isoforms in healthy subjects  
According to the results previously provided by our group in a smaller population73, 
beyond the native and unchanged HSA form, other 7 monomeric isoforms with one or 
two alterations were identified: HSA-DA, HSA-L, HSA+CYS, HSA+SO2H, 
HSA+GLYC, HSA+CYS-DA, HSA+CYS+GLYC (Figure 8a). The molecular weight 
of each HSA isoform and the corresponding functional alteration is reported in Table 3. 
The hypnotized sites and types of structural alterations previously reported were further 
confirmed by protein  digestion followed by a 2D LC-ESI-MSMS analysis. 
 
Table 3. Human serum albumin (HSA) isoforms identified in plasma samples: 
molecular weight, structural alterations and functional consequences. 
MW 
(Da) 
Isoforms Structural alteration Functional 
consequence 
Ref. 
-180 HSA-DA N-terminal truncated (-Asp-Ala) 
Loss of chelating function, 
loss of free radical 
scavenging activity 
71 
-110 HSA-L C-terminal truncated (-Leu) Impaired protein stability, 
shorter half-life 30 
-60 HSA+CYS-DA 
Cysteinylated and N-
terminal truncated (-Asp-
Ala) 
Loss of antioxidant activity, 
loss of chelating function 34, 71 
66439 Native HSA Native form of HSA with fully preserved non-oncotic activity 
+30 HSA+SO2H Sulfinylated 
Irreversible oxidation of Cys-
34 residue 34, 30 
+120 HSA+CYS Cysteinylated Loss of antioxidant activity 34, 74 
+160 HSA+GLY Glycosylated Impaired binding activity, 
conformational alteration 66 
+280 HSA+CYS+GLY Cysteinylated and glycosylated 
Impaired antioxidant and 
binding activity, 
conformational alteration 34,74, 66 
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Figure 8. Deconvoluted ESI-MS spectra from an healthy control (A) and a cirrhotic 
patient (B). In each mass spectra, besides the native HSA, additional seven isoforms 
were detected: HSA-DA, HSA-L, HSA+CYS, HSA+SO2H, HSA+GLYC, HAS+CYS-DA, 
HSA+CYS+GLYC. 
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2.1.2 Monomeric HSA isoforms in patients with cirrhosis 
The HSA isoforms identified in the control group were detected in cirrhotic patients as 
well (Figure 8B). Otherwise, the evaluation of the relative amount of each identified 
isoform showed that impaired HSA isoforms were more abundant in hospitalized 
patients and outpatients with cirrhosis than in healthy controls. Among these isoforms 
the cysteinylated (HSA+CYS, HSA+CYS+GLYC, HSA+CYS-DA) and glycosylated  
(HSA+GLYC) forms were the most abundant (Table 4). As a result, a significant 
reduction of the native, unchanged HSA relative abundance was detected in both groups 
of patients with respect to control population (Figure 9).  
 
 
 
 
Figure 9. Relative amount of native HSA isoform in healthy controls, outpatients, and 
hospitalized patients with cirrhosis expressed as individual values and blox plots of 
mean, range, and 95% confidence interval. 
 
 
Although almost all HSA isoforms were more abundant in hospitalized patients than 
outpatients only the HSA+GLYC+CYS isoform reached the statistical significance 
(Table 4).  
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Table 4. Relative abundance of HSA isoforms in healthy controls (n=44), outpatients 
(n=35) and hospitalized patients with cirrhosis(n=133). 
HSA-DA: N-terminal truncated (-Asp-Ala); HSA-L: C-terminal truncated (-Leu); HSA+CYS-
DA: cysteinylated and N-terminal truncated (-Asp-Ala); native HSA: native form of HSA; 
HSA+SO2H: sulfinilated; HSA+CYS: cysteinylated; HSA+GLYC: glycosylated; 
HSA+CYS+GLYC: cysteinylated and glycosylated.Data were expressed as mean ± SD. Each 
isoform relative abundance was calculated as percent over total HSA isoforms, ANOVA 
posthoc analysis. *P<0.05 versus healthy controls. ƗP<0.05 versus outpatients with cirrhosis  
 
2.1.3 Correlation between HSA isoforms and disease severity 
Following the correlation analysis no association were found between the HSA-DA, 
HSA-L, and both MELD and Child-Pugh scores. On the contrary, all the HSA isoforms 
with structural changes at the Cys-34 residue level (HSA+CYS, HSA+CYS-DA, 
HSA+CYS-GLYC, and HSA+SO2H) directly correlated with the MELD score (Table 
5). The same association was found with the Child- Pugh score, with the exception of 
the HSA+CYS and HSA+CYS+GLYC isoforms. Contrariwise, an inverse correlation 
was found between the HSA+GLYC isoform and MELD or Child-Pugh scores. As a 
Isoform Healthy 
Controls 
N=44 
Outpatients 
 
N=35 
Hospitalized 
Patients   
N=133 
HSA-DA (%) 2.5±0.7 2.4±0.7 2.3±0.9 
HSA-L (%) 3.1±1.2 2.4±1.3 2.3±1.9 
HSA+CYS-DA (%) 1.9±0.3 2.3±0.4* 2.1±0.8* 
Native HSA 52.4±2.6 45.9±5.6* 43.2±6.2* 
HSA+SO2H (%) 7.3±1.3 8.0±1.1 7.9±2.4 
HSA+CYS (%) 19.9±4.4 24.3±7.3* 26.0±6.3* 
HSA+GLYC (%) 9.1±1.3 9.6±2.6 9.8±3.1* 
HSA+CYS+GLYC (%) 3.8±0.8 5.1±1.6* 6.3±2.1*Ɨ 
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result of the above reported association, a strong negative correlation was found 
between the relative abundance of the native HSA isoform and both prognostic scores.  
 
Table 5.Analysis of the correlation between relative abundance of HSA isoforms and 
MELD and Child Pugh Scores in the entire population of cirrhotic patients (n=168) 
 MELD Child-Pugh 
Correlation 
coefficient 
P value Correlation 
coefficient P value 
HSA-DA (%) 0.045 0.584 0.003 0.970 
HSA-L (%) -0.040 0.627 -0.057 0.478 
HSA+CYS-DA 
(%) 
0.266 0.001 0.201 0.012 
Native HSA (%) -0.318 <0.001 -0.263 0.001 
HSA+SO2H (%) 0.259 0.001 0.265 0.001 
HSA+ CYS 0.219 0.007 0.149 0.064 
HSA+GLYC -0.220 0.007 -0.195 0.015 
HSA+CYS+GLYC 0.181 0.026 0.120 0.136 
HSA-DA: N-terminal truncated (-Asp-Ala); HSA-L: C-terminal truncated (-Leu); HSA+CYS-DA: 
cysteinylated and N-terminal truncated (-Asp-Ala); native HSA: native form of HSA; HSA+SO2H: 
sulfinilated; HSA+CYS: cysteinylated; HSA+GLYC: glycosylated; HSA+CYS+GLYC: cysteinylated and 
glycosylated 
 
2.1.4 Relationship between HSA isoforms and complications of liver cirrhosis 
We first compared the relative abundance of the monomeric and dimeric HSA isoforms 
in patients with or without the following complications: ascites, renal impairment and 
bacterial infection (Table 6). As only few patients presented variceal bleeding, HCC and 
hepatic encephalopathy (Table 2), we decided to exclude these complications from the 
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analysis. For each complication, following univariate analysis a multivariate logistic 
regression was performed in order to identify HSA isoforms independently associated to 
the specific complication (Table7). 
 
Ascites. As expected, patients with ascites showed higher value of MELD and Child-
Pugh scores, furthermore they presented a significantly higher relative abundance of 
HSA-DA, HSA+CYS-DA, HSA+SO2H and a significant reduced abundance of 
HSA+GLYC respect to those without the complication. Also the native, unchanged, 
HSA isoform was significantly lower in patients with ascites with respect to patients not 
presenting this complication at study inclusion. All variable significantly associated to 
the presence of ascites at univariate analysis were entered in the multivariate logistic 
regression model with the exception of the Child-Pugh score which account for the 
presence of ascites in its calculation. The analysis showed that the relative amount of 
the HSA+CYS-DA isoform is independently associated to presence of ascites. 
 
Renal Impairment. Patients with serum creatinine level higher than 1.5 mg/dL have an 
higher MELD and Child Pugh scores, instead for the isoforms. Additionally they 
presented higher relative amount of the HSA+CYS, HSA+CYS-DA, HSA+SO2H and 
HSA+GLYC isoforms with respect to patients without renal impairment. As for patients 
with ascites, the native HSA isoform was significantly reduced in patients with renal 
impairment. The multivariate logistic regression analysis, in which the MELD score, 
which account for serum creatinine level was  not considered, showed that the 
HSA+CYS and HSA+SO2H isoforms  were independently associated with the presence 
of renal impairment. 
 
Bacterial Infection. Although not statistically significant, prognostic scores tended to 
be higher in patients with bacterial infection with respect to patients without bacterial 
infection. On the contrary the relative abundance of HSA-L and HSA+CYS-DA 
isoforms were significantly increased in patients with bacterial infections, while the 
native HSA resulted significantly reduced. From the multivariate logistic regression 
analysis, only the HSA+CYS-DA isoform resulted to be independently associated with 
the presence of bacterial infections. 
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Table 6. Univariate analysis of the association between age, disease severity scores and human serum albumin (HSA) isoforms relative 
abundance whit  ascites, renal dysfunction, or bacterial infection in hospitalized cirrhotic patients. 
  Ascites  Renal impairment  Bacterial infection 
  Yes 
(N = 66) 
No 
(N = 67) p 
 Yes 
(N = 33) 
No 
(N = 100) p 
 Yes 
(N = 41) 
No 
(N = 92) p 
Age (years)  58 ± 11 61 ± 12 0.092  59 ± 10 60 ± 12 0.733  61 ± 13 59 ± 11 0.255 
MELD score  18.6 ± 6.9 15.1 ± 7.2 0.001  22.5 ± 7.1 15.02 ± 6.3 0.014  18.6 ± 7.1 16.1 ± 7.2 0.286 
Child-Pugh score  9.1 ± 1.5 7.4 ± 1.8 0.006  8.9 ± 2.0 8.1 ± 1.8 0.001  8.5 ± 1.8 8.1 ± 1.9 0.073 
HSA-DA (%)  2.6 ± 0.9 2.1 ± 0.9 0.001  2.4 ± 1.0 2.3 ± 0.9 0.413  2.4 ± 1.0 2.3 ± 0.9 0.354 
HSA-L (%)  2.3 ± 2.0 2.4 ± 1.9 0.936  2.0 ± 1.0 2.5 ± 2.1 0.203  1.9 ± 1.0 2.5 ± 2.2 0.040 
HSA+CYS−DA (%)  2.5 ± 0.9 1.8 ± 0.7 0.001  2.6 ± 0.9 2.0 ± 0.7 0.001  2.4 ± 1.0 2.0 ± 0.7 0.006 
Native HSA (%)  42.1 ± 6.4 44.2 ± 5.6 0.049  39.9 ± 5.9 44.3 ± 5.9 0.001  41.2 ± 6.3 44.1 ± 5.9 0.017 
HSA+SO2H (%)  8.6 ± 2.1 7.1 ± 2.4 0.001  8.7 ± 2.4 7.6 ± 2.3 0.021  8.5 ± 2.6 7.6 ± 2.2 0.067 
HSA+CYS (%)  26.4 ± 6.6 25.5 ± 6.0 0.435  29.0 ± 7.2 25.0 ± 5.7 0.008  27.5 ± 6.4 25.3 ± 6.2 0.074 
HSA+GLYC (%)  9.2 ± 2.6 10.5 ± 3.5 0.019  8.9 ± 2.8 10.2 ± 3.2 0.041  9.2 ± 2.9 10.1 ± 3.2 0.108 
HSA+CYS+GLYC (%)  6.1 ± 2.0 6.4 ± 2.1 0.518  6.5 ± 1.7 6.2 ± 2.2 0.468  6.8 ± 2.1 6.0 ± 2.0 0.070 
MELD: model for end stage liver disease; HSA-DA: N-terminal truncated (-Asp-Ala); HSA-L: C-terminal truncated (-Leu); HSA+CYS-DA: cysteinylated and N-
terminal truncated (-Asp-Ala); native HSA: native form of HSA; HSA+SO2H: sulfinylated; HSA+CYS: cysteinylated; HSA+GLYC: glycosylated; HSA+CYS+GLYC: 
cysteinylated and glycosylated. 
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Table 7. Binary logistic regression model with backward selection of variables 
independently associated to ascites, renal impairment and bacterial infection in 
hospitalized cirrhotic patients. 
 
 Ascitesa Renal impairmentb Bacterial infectionc 
 OR (95% CI) p OR (95% CI) p OR (95% CI) p 
HSA+CYS−DA 2,36 (1,25-4,46) 0,008 - - 1,88 (1,16-3,05) 0,010 
HSA+SO2H - - 1,36 (1,11-1,66) 0,003 - - 
HSA+CYS - - 1,15 (1,06-1,24) 0,001 - - 
HSA+CYS−DA: cysteinylated and N-terminal truncated (-Asp-Ala); HSA+SO2H: sulfinylated; 
HSA+CYS: cysteinylated; aVariables entered on step one: MELD score, HSA-DA, HSA+CYS-DA, 
HSA, HSA+SO2H, HSA+GLYC. bVariables entered on step one: Child-Pugh score, HSA+CYS-DA, 
HSA, HSA+ HSA+SO2H, HSA+CYS, HSA+GLYC. cVariables entered on step one: HSA-L, 
HSA+CYS-DA, HSA  
 
2.1.5 Relationship between HSA isoforms and diabetes mellitus 
A comparison between relative abundances of HSA isoforms was performed among 
hospitalized cirrhotic patients with and without type 2 diabetes mellitus and control 
population. A reduction of the native, unchanged HSA was observed in cirrhotic 
patients with diabetes with respect to those without, the same trend was observed for the 
truncated isoforms as HSA-DA and HSA-L in patients with diabetes with respect to 
those without. As expected, the glycosylated isoforms (HSA+GLYC and 
HSA+CYS+GLYC)  showed an higher relative abundance in diabetic patients with 
respect to patients with preserved glycemic control, instead no differences were 
observed for the isoforms with oxidation of Cys-34 residue  among the two group of 
hospitalized patients (Table 8). 
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Table 8. Relative abundance of human serum albumin (HSA) isoforms in healthy 
controls and hospitalized cirrhotic patients divided according to the presence or not of 
type II diabetes mellitus. 
 
 Controls  Hospitalized cirrhotic patients 
 
(n = 44) 
 Without diabetes 
(n = 86) 
With diabetes  
 (n = 47) 
HSA−DA (%) 2,35 ± 0,45 2.51 ± 0.85 2.02± 0.97* 
HSA−L (%) 2,94± 1,11 2.69 ± 2.27 1.74± 0.80*§ 
HAS+CYS−DA (%) 1,67± 0,21 2.21 ± 0.85§ 2.03± 0.79 
Native HSA (%) 50,70± 4,70 44.37 ± 6.08§ 40.98± 5.50*§ 
HSA+SO2H (%) 6,90± 1,03 8.16 ± 2.34 7.38± 2.33 
HSA+CYS (%) 22,25± 4,84 25.28 ± 6.32 27.18± 6.16§ 
HSA+GLYC (%) 8,99± 1,28 9.21 ± 2.78 10.94± 3.41*§ 
HSA+CYS+GLYC (%) 4,17± 1,34 5.43 ± 1.37§ 7.71± 2.24*§ 
HSA‒DA: N-terminal truncated (-Asp-Ala); HSA-L: C-terminal truncated (-Lys); HSA+CYS-DA: 
cysteinylated and N-terminal truncated (-Asp-Ala); native HSA: native form of HSA; HSA+SO2H: 
sulfinylated; HSA+CYS: cysteinylated; HSA+GLYC: glycosylated; HSA+CYS+GLYC: cysteinylated and 
glycosylated. *p<0,020 vs cirrhotics without diabetes; §p<0,050 vs controls. 
 
2.1.6 Monomeric HSA isoforms and 1-year survival  
After 1-year of follow-up 77 (60%) of hospitalized patients were still alive. In a 
preliminary analysis the Cox proportional hazard method was used to compare the 
association between HSA isoforms or serum albumin concentration and survival rate. 
Among all the HSA isoforms, the HSA+CYS-DA and the native HSA significantly re 
stratified the risk of death within 1 year (Table 9).  
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Table 9. Univariate Cox regression analysis of the association between HSA isoforms, 
serum albumin concentration and 1-years survival in admitted patients.  
 
 OR 95% CI p 
Serum albumin (g/dl) 0.877 0.575-1.337 0.541 
HSA-DA (%) 1.293 0.962-1.737 0.088 
HSA-L (%) 0.931 0.777-1.116 0.439 
HSA+CYS-DA (%) 1.566 1.113-2.203 0.010 
Native HSA (%) 0.944 0.900-0.990 0.019 
HSA+SO2H (%) 1.106 0.986-1.241 0.085 
HSA+CYS (%) 1.021 0.974-1.069 0.389 
HSA+GLYC (%) 1.001 0.917-1.092 0.986 
HSA+CYS+GLYC (%) 1.095 0.964-1.244 0.163 
HSA‒DA: N-terminal truncated (-Asp-Ala); HSA-L: C-terminal truncated (-Lys); HSA+CYS-DA: 
cysteinylated and N-terminal truncated (-Asp-Ala); native HSA: native form of HSA; HSA+SO2H: 
sulfinylated; HSA+CYS: cysteinylated; HSA+GLYC: glycosylated; HSA+CYS+GLYC: cysteinylated and 
glycosylated. 
 
Then, we categorized HSA+CYS-DA and the native HSA in relation to their best-cutoff 
calculated by the ROC curve analysis. Finally survival curves for HSA+CYS-DA, 
native HSA and serum albumin concentration were plotted according to the Kaplan 
Meyer’s method followed by the log-rank test to compare the survival rate. Cirrhotic 
patients presenting a relative amount of HSA+CYS-DA below 2.18% displayed a 
significant higher survival (10.4 ± 0.37 vs. 7.72 ± 0.64 months; P=0.001) with respect to 
patients with higher value (Figure 10A). Also patients with a relative amount of native 
HSA higher than 44,38% presented a longer survival with respect to those with a lower 
amount (10.30 ± 0.48 vs 8.55 ± 0.50 months; P=0.002) (Figure 10B). The best cut-off of 
total serum albumin concentration for 1-year survival was 4.05 g/dl in our series. The 
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Kaplan Meier survival analyses showed that cirrhotic patients with total albumin 
concentration below or equal 4.05 g/dl had a worse survival with respect to patients 
with values above the cut-off, however this result did not achieve a statistical 
significance (10.16 ± 0.65 vs 9.06 ± 0.43 months; P=0.063) (Figure 10C). 
 
 
 
Figure 10. Kaplan-Meier’s survival curves for HSA+CYS-DA (A), native HSA (B), and 
serum albumin concentration (C) in hospitalized cirrhotic patients dichotomized 
according to their best cut-off evaluated by ROC curve analysis. 
 
 
  
2.2 Dimeric HSA isoforms in healthy subjects and hospitalized patients with 
cirrhosis 
The formation of HSA dimer was proposed in the literature as a structural modification 
of the molecule promoted by a pro oxidant environment
plasma samples from healthy controls and hospitalized patients with cirrhosis in order 
to evaluate if such alteration occurs in physiological c
associated to an increase of HSA dimers formation. 
2.2.1 Identification of HSA 
The presence of dimeric HSA iso
volunteers and cirrhotic patients by means of native gel electrophoresis followed by 
western blot analysis. from the enrolled population
a polyachrylamide native gel. 
molecular weight 65 KDa) and the dimeric 
identified in plasma samples from
signal intensity corresponding to the dimeric form seems to be higher in patients than in 
controls. 
Figure 11. Electrophoresis of a native gel run under not
conditions. Lines 1-3: plasma 
from cirrhotic patients. 
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ondition and if cirrhosis could
 
dimers 
form was evaluated in plasma samples from  healthy 
 were undergone to electrophoresis 
As showed in figure 11 the monomeric 
(expected molecular weight 130 KD
 both controls and cirrhotic subjects. 
 
 
-denaturing and not
samples from healthy patients; lines 4-6 
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 be 
in 
(expected 
a) were 
Additionally the 
-reducing 
plasma samples 
  
The presence of HSA dimeric form
Indeed, in the mass spectrum of control and patients a signal at the expected mo
weight was identified. Moreover, comparable to the results provided by the western blot 
analysis, the dimers signal intensity was found to be higher  in cirrhotic patients than 
healthy controls (Figure 12
 
Figure 12. MALDI TOF mass spectra ref
samples from an healthy control (Panel A) and a cirrhotic patient (Panel B)
 
2.2.2 Characterization of the 
The Cys-34 residue represent the main antioxidant si
it may be the target of oxidative modification 
 was further confirmed by MALDI TOF analysis 
).  
erred resulted from the analysis of plasma 
molecular site involved in the dimerization process 
te of the HSA molecule, therefore,
leading to HSA dimers formation. 
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Namely, we hypothesized that 
disulfide bridge between two HSA molecules at the Cys
Such hypothesis was confirmed by the LC
plasma tryptic digestion, performed under non reducing conditions
the disulfide bonds, a dipeptide, arising from the interaction of two C
two different HSA molecule was found (Figure
identified in the previous experiment disappeared when the enzymatic digestion was 
performed under reducing conditions
Figure 13. Sequence and 
trypsin cleavage of a plasma sample. 
the dimerization process may involve the formation of a 
-34 level. 
-ESI-MSMS analysis in which, following 
, in order to preserve 
y
 13). Confirming this result the dipeptide 
. 
LC-ESI-MSMS mass spectra of the dipeptide generated by 
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2.2.3 Role of oxidative stress in the formation of HSA dimers
In order to confirm that oxidative stress plays a major role in the dimerization process of 
the HSA molecule, a plasm
increased concentration of 
intervals. The analysis of the 
that, following  24 hours of incubation 
abundance of the highly oxidize 
concentration of the oxidant agent. Ove
HSA isoforms were observed 
14). Analogously, also the percentage of dimeric HSA isoform increased in a time and 
dose dependent manner following exposure 
environment (Figure 14).  
 
 
Figure 14. Relative abundance of HSA monomeric isoforms 
incubated for 24 hours with 
relative abundance in plasma sa
concentration of t-BuOOH 
 
 
 
 
a sample from an health volunteer was incubated with 
tert-Butyl hydroperoxide (t-BuOOH) for different time
reaction products, performed by  LC-ESI
with 0.2 and 2.0 mM of t-BuOOH
HSA-SO2H isoform increased proportionally to the 
rall a rise of all the monomeric 
in parallel to a marked reduction of native HSA
of the plasma sample to a pr
in plasma sample 
t-BuOOH at different concentration (Panel A)
mple after 24 hours incubation with increasing 
(Panel B).  
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2.2.4. Relative abundance of dimeric HSA isoforms in healthy subjects and hospitalized 
patients with cirrhosis 
The relative abundance of the dimeric HSA isoforms was evaluated in the whole 
population of 133 cirrhotic patients and compared to that measured in 44 healthy 
controls.  We focused on the three more represented dimeric HSA isoform and the 
corresponding monomeric isoforms. Namely we quantified the relative abundance of 
the isoforms  resulted from the homodimerization of HSA-DA (dimeric HSA-DA, 
dHSA-DA), HSA-L (dimeric HSA-L, dHSA-L) and native HSA (dimeric HSA, dHSA) 
monomeric isoforms (Table 9). 
 
 
Table 9. More represented human serum albumin (HSA) dimeric isoforms included in 
the analysis: molecular weight, structural alteration and functional consequences. 
MW (Da) Isoforms Structural 
alterations 
Functional 
consequences 
Ref. 
+66090 dHSA-DA 
Homodimeric form 
of the N-terminal 
truncated(-Asp-Ala) 
Loss of chelating 
function, free radical 
scavenging activity and   
antioxidant activity 
71,84 
+66230 dHSA-L 
Homodimeric form 
of the C-terminal 
truncated(-Leu) 
Impaired protein stability, 
shorter half-life, loss of 
antioxidant activity 
30,84 
+66460 dHSA 
Homodimeric form 
of the native human 
serum albumin 
Loss of antioxidant 
activity 
84 
dHSA-DA: homodimeric form of the N-terminal truncated human serum albumin; dHSA-L: homodimeric 
form of the C-terminal truncated human serum albumin; dHSA: homodimeric form of the native human 
serum albumin. 
 
The analysis of the mass spectra revealed that the extent of HSA dimerization was 
significantly greater in patients than controls, while among the corresponding 
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monomeric isoforms, only the native unchanged HSA was significantly reduced in 
cirrhotic subjects (Table 10). 
 
Table 10. Relative abundance of dimeric human serum albumin (HSA) isoforms in 
healthy controls (n=44) and patients with cirrhosis (n=133). 
 Healthy controls 
(N = 44) 
Patients with cirrhosis 
(N = 133) 
p 
HSA-DA (%) 4.0 ± 0.6 4.3 ± 2.3 0.534 
HSA-L (%) 5.2 ± 1.8 4.4 ± 6.2 0.281 
Native HSA (%) 86.3 ± 2.3 80.9 ± 7.7 0.002 
dHSA-DA (%) 2.8 ± 0.9 4.8 ± 2.1 0.000 
dHSA-L (%) 1.1 ± 0.6 2.2 ± 1.3 0.000 
dHSA (%) 0.6 ± 0.4 3.1 ± 3.7 0.002 
HSA-DA: N-terminal truncated (-Asp-Ala); HSA-L: C-terminal truncated (-Leu); native HSA: native form 
of HSA; dHSA-DA: homodimeric form of the N-terminal truncated human serum albumin; dHSA-L: 
homodimeric form of the C-terminal truncated human serum albumin; dHSA: homodimeric form of the 
native human serum albumin. 
 
2.2.5. Correlation between dimeric HSA isoforms and disease severity 
While no correlations were found between the monomeric HSA-DA and HSA-L 
isoforms and disease severity, as assessed by the MELD and Child Pugh scores, a 
negative correlation was found between the relative abundance of the native, 
unchanged, HSA and both prognostic scores, thus confirming the previous findings and 
supporting the idea that the more severe is cirrhosis, the lower is the circulating HSA 
with a fully preserved molecular structure.  
Contrary to the monomeric isoforms, all the dimeric HSA isoforms significantly 
correlated with the MELD and Child-Pugh scores (Table 11). 
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Table 11. Analysis of correlation between relative abundance of human serum albumin 
(HSA) isoforms and MELD and Child-Pugh scores. 
 
 MELD  Child-Pugh 
 Spearman rho P  Spearman rho p 
HSA-DA (%) 0,091 0,315  0,088 0,334 
HSA-L (%) -0,205 0,023  -0,186 0,040 
Native HSA (%) -0,412 0,000  -0,358 0,000 
dHSA-DA (%) 0,380 0,000  0,344 0,000 
dHSA-L (%) 0,369 0,000  0,362 0,000 
dHSA (%) 0,504 0,000  0,455 0,000 
HSA-DA: N-terminal truncated (-Asp-Ala); HSA-L: C-terminal truncated (-Leu); native HSA: native form 
of HSA; dHSA-DA: homodimeric form of the N-terminal truncated human serum albumin; dHSA-L: 
homodimeric form of the C-terminal truncated human serum albumin; dHSA: homodimeric form of the 
native human serum albumin. 
 
2.2.6 Relationships between HSA isoforms and liver cirrhosis complications 
As for the monomeric HSA isoform, we evaluated the association between the relative 
abundance of the dimeric HSA isoform and the presence of ascites, renal impairment 
and bacterial infection (Table 12), which were the more frequent complication recorded 
at study inclusion (Table 2). Following univariate analysis, a multivariate logistic 
regression was performed to identify HSA dimeric and/or monomeric isoforms 
independently associated to the presence of clinical complications of cirrhosis.  
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 Ascites. Besides the higher prognostic scores, as reported before, patients with ascites 
had significantly greater relative amounts of dHSA-DA isoform than compensated  
patients, while the native HSA was significantly lower (Table 12).  
The multivariate logistic regression analysis, including as covariates the native HSA, 
the dHSA-DA isoform and MELD score showed that the dHSA-DA isoform was 
independently associated with the presence of ascites irrespective of the severity of 
cirrhosis (OR 1.321; CI 95% 1.071-1.630; p=0.009). 
 
Renal impairment. Patients with renal impairment presented an higher relative 
abundance of the dHSA-DA and dHSA isoforms (Table 13), together with significantly 
increased MELD and Child-Pugh scores as previously reported. The multivariate 
logistic regression analysis including the native HSA, the dHSA-DA, the dHSA 
isoforms and Child-Pugh score showed that the dHSA-DA was independently 
associated with the presence of renal impairment, irrespective of the disease severity as 
assessed by the Child-Pugh score (OR 1.377; CI 95% 1.084-1.750; p=0.009). 
 
Bacterial infection. Only the relative abundance of the dHSA-DA isoform was 
significantly increased in patients presenting bacterial infection at study inclusion. The 
subsequent multivariate analysis, including the MELD score as covariate,  showed that 
such association was independent from the severity of the disease (OR 1.537; CI 95% 
1.229-1.922; p<0.001). 
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Table 12. The relative abundances of human serum albumin (HSA) dimeric isoforms and their respective monomers in cirrhotic patients with or 
without ascites, renal dysfunction, or bacterial infection. 
 
  
Ascites  Renal impairment 
 Bacterial infection 
  Yes 
(N = 66) 
No 
(N = 67) 
p 
 Yes 
(N = 33) 
No 
(N = 100) 
p 
 Yes 
(N = 41) 
No 
(N = 92) 
P 
HSA-DA (%) 
 
4.7 ± 1.9 3.9 ± 2.6 0.050 
 
4.6 ± 2.1 4.2 ± 2.4 0.472 
 
4.6 ± 2.1 4.2 ± 2.5 0.338 
HSA-L (%)  4.8 ± 8.2 4.1 ± 3.2 0.536  3.5 ± 2.0 4.8 ± 7.0 0.119  3.5 ± 1.8 4.9 ± 7.3 0.103 
Native HSA (%)  79.0 ± 9.2 82.7 ± 5.3 0.008  79.1 ± 4.6 81.6 ± 8.4 0.042  79.7 ± 5.0 81.4 ± 8.6 0.175 
dHSA-DA (%)  5.4 ± 2.0 4.2 ± 2.1 0.001  5.9 ± 2.0 4.4 ± 1.9 0.001  6.0 ± 2.3 4.3 ± 1.8 0.000 
dHSA-L (%)  2.3 ± 1.1 2.1 ± 1.4 0.328  2.9 ± 1.5 2.1 ± 1.2 0.120  2.5 ± 1.2 2.1 ± 1.3 0.065 
dHSA (%)  3.7 ± 4.8 2.6 ± 2.0 0.138  4.4 ± 3.0 2.7 ± 3.9 0.016  3.6 ± 2.2 2.9 ± 4.2 0.219 
HSA-DA: N-terminal truncated (-Asp-Ala); HSA-L: C-terminal truncated (-Leu); native HSA: native form of HSA; dHSA-DA: homodimeric form of the N-terminal truncated human 
serum albumin; dHSA-L: homodimeric form of the C-terminal truncated human serum albumin; dHSA: homodimeric form of the native human serum albumin. 
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2.2.7 Association between dimeric HSA isoforms and 1- year patients survival 
We compared the association between each dimeric HSA isoform with the survival rate 
by univariate analysis using the Cox proportional hazard method. Among the 
monomeric isoforms only the native HSA was significantly associated to 1-year 
survival, on the contrary the dimeric isoforms did not stratify the risk of death within 1-
year, although the association between dHSA-DA and patients prognosis was very close 
to the statistical significance (Table 13). 
 
Table 13. Univariate Cox regression analysis of the association between monomeric 
and dimeric HSA isoforms and 1-years survival in hospitalized patients with cirrhosis.  
 
 OR 95% CI p 
HAS-DA (%) 1.085 0.994-1.085 0.068 
HAS-L (%) 1.003 0.960-1.047 0.900 
Native HSA (%) 0.974 0.949-0.999 0.040 
dHSA-DA (%) 1.139 0.996-1.302 0.057 
dHSA-L (%) 1.134 0.918-1.402 0.243 
dHSA (%) 1.032 0.955-1.115 0.430 
HSA-DA: N-terminal truncated (-Asp-Ala); HSA-L: C-terminal truncated (-Leu); native HSA: native form 
of HSA; dHSA-DA: homodimeric form of the N-terminal truncated human serum albumin; dHSA-L: 
homodimeric form of the C-terminal truncated human serum albumin; dHSA: homodimeric form of the 
native human serum albumin. 
 
 
In order to plot survival curve the native HSA and the dHSA-DA isoforms were 
categorized according to their best cut-off determined through the ROC curve analysis. 
The survival analysis, performed according to the Kaplan Meier method, showed that  
patients with relative amount of dHSA-DA lower or equal than 4.74% had a 
significantly higher survival than their counterparts (10.22 ± 0.44 vs 8.28 ± 0.56 
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months, p=0.001) (Figure 15, panel A). Similarly, The analysis of survival curves 
confirmed the prognostic relevance of the native HSA isoform emerged from the Cox 
analysis. Namely, patient with relative amount of native HSA higher than 80.28% had a 
significant higher survival rate then patients with native HSA relative amount below or 
equal to 80.28% (9.94 ± 0.42 vs 8.33 ± 0.64 months, p=0.045) (Figure 15, panel B),  
thus confirming its prognostic role emerged from the analysis of all monomeric HSA 
isoforms previously performed.  
 
 
 
 
 
 
Figure 15. Kaplan-Meier survival curves for dHSA-DA  and native HSA dichotomized 
according to their best cut-off. 
 
 
 
 
 
 
 
 
 
  
3. Functional alterations to the HSA molecule 
3.1 Ischemia modified albumin
patients with cirrhosis. 
IMA levels were measured in 127 out of 133 hospitalized cirrhotic patients, for which 
heparinized plasma samples were available, and 44 healthy controls.
Circulating IMA levels were significantly higher in cirrhotic patients as compared to 
healthy controls (0.511±0.118 vs 0.404±0.110 ABSU, 
After the normalization for the total se
significantly higher in patients than controls
P<0.001) (Figure 16, panel B
 
Figure 16. Tukey boxes and whiskers plots
data of circulating IMA (a) expre
albumin concentration) (b) levels in cirrhotic patients (
 
3.2 Correlation between IMA and IMA
Following the correlation analysis 
levels and the severity of disease
Contrariwise a significant association was found between IMAr and the
score, however this was an expected association since the calculation of both parameters 
accounts for the total serum albumin concen
 
 (IMA) level in healthy controls and hospitalized 
 
P< 0.001) (Figure 16
rum albumin concentration, IMAr
 (0.154±0.0058vs 0.090±0.024 ABSU,
).  
 (median and interquartile range), individual 
ssed in arbitrary units (ABSU) and IMAr (IMA/serum 
n=127) and controls (
r level and disease severity 
no significant associations were found between
 as assessed by both MELD and Child Pugh scores
tration (Table 13). 
60 
, panel A). 
 remained 
 
 
n=44). 
 IMA 
. 
 Child Pugh 
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Table 13. Correlations between ischemia modified albumin (IMA), IMA to albumin 
ratio (IMAr) levels, MELD and Child-Pugh scores. 
 MELD  Child-Pugh 
Correlation coefficient p Correlation coefficient p 
IMA (ABSU) -0.016 0.856 0.123 0.169 
IMAr (Ratio) -0.046 0.606 0.204 0.021 
 
3.3 Relationship between IMA, IMAr levels and complications of liver cirrhosis 
IMA and IMAr levels were not associated to the presence of ascites or renal impairment 
(Table 14). On the contrary, IMA and IMAr were significantly associated to the 
presence of bacterial infections at hospital admission (Figure 17).  Additionally, IMA 
and IMAr levels rise gradually from healthy controls to cirrhotic patients, reaching the 
highest value in cirrhotic patients with bacterial infection, being all comparisons 
statistically significant (Figure 17).  
 
Table 14. Ischemia modified albumin (IMA) and IMA to serum albumin ratio (IMAr) 
levels in patients with or without ascites or renal impairment at hospital admission 
  Ascites  Renal failure 
  Yes 
(n=62) 
No 
(n=65) 
p 
 Yes 
(n=33) 
No 
(n=100) 
p 
IMA (ABSU) 
 
0.51± 0.12 0.507± 0.115 0.720 
 
0.521± 0.133 0.508 ± 0.114 0.602 
IMAr (ratio)  0.16± 0.06 0.151± 0.060 0.564  0.157± 0.064 0.153 ± 0.057 0.733 
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Figure 17. Tukey boxes and whiskers plots (median and interquartile range ), single 
values for each patient of IMA (panel A) and IMAR (panel B) of controls (n=44), 
cirrhotic patients (87), and cirrhotic patients with bacterial infections (40).  
 
We than compared the discriminating performance against the presence of bacterial 
infection of all parameters we found to be significantly increased in infected patients, 
namely IMA, IMAr, CRP levels and CYS-DA relative abundance. The ROC curve 
analysis showed that  IMA (AUROC 0.746, 95% CI 0.646-0.845) and CRP (AUROC 
0.746, 95% CI 0.654-0.838) levels had a good diagnostic power, while IMAr (AUROC 
0.722, 95% CI 0.627-0.818) and HAS+CYS-DA (AUROC 0.604, 95% CI 0.489-0.718) 
were found to be less efficient in discriminating the presence of bacterial infection. 
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Additionally the multivariate binary logistic regression showed that IMA (OR 2.411, 
95% CI 1.520-3.824 p=0.001) and CRP  (OR 1.203, 95% CI 1.013-1427, P=0.035) were 
both independently associated to the presence of bacterial infection.  
 
3.4 Association between IMA, IMAr and 1-year survival  
The univariate analysis, performed through the Cox proportional hazard method, 
showed that IMA (OR 0.863, 95% CI 0.078-9.596, p=0.905) and IMAr (OR 0.784, 95% 
CI 0.007-92.155 p=0.920) levels were not associated to the overall 1-year survival rate. 
(Data are not shown). 
 
3.5 IMA levels in rats with experimental cirrhosis and bacterial infection  
In order to further confirm the association between the functional impairment of the N-
terminal portion of the HSA molecule and the presence of bacterial infection, we 
measured IMA levels in cirrhotic rats in which bacterial infection were mimicked by the 
administration of a single sub-lethal dose of LPS. As shown in figure18, cirrhotic rats 
presented significantly higher baseline IMA levels with respect to healthy controls rats 
(0.484±0.097 vs 0.773±0.059 ABSU, p=0.001). After a single intravenous injection of 
LPS (10 mg/kg), while the IMA level at 2 and 6 hours only tended to increase in healthy 
rats without significant changes from baseline, it rose significantly up to 0.998 ± 0.087 
ABSU (P = 0.001) in rats with cirrhosis. 
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Figure 18. Circulating Ischemia modified albumin (IMA) level in healthy (n=6) and 
cirrhotic rats (n=6) at baseline and after 2, and 6 hours from a single intravenous 
lipopolysaccharide (LPS, 10mg/kg) injection. Data were expressed as mean ± standard 
error mean.  
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DISCUSSION 
 
In the present study the identification and quantification of structural and functional 
alterations to the HSA molecule were performed for the first time in a large cohort of 
patients with advanced cirrhosis admitted to the hospital for the onset of an acute 
clinical complication of the disease. By using advanced mass spectrometric technique, 
besides post-transcriptional changes to the albumin molecule previously reported in 
other clinical settings74, new oxidative products, never reported before in patients with 
cirrhosis, were identified and characterized. Thus, the overall analysis of the albumin 
structural and functional integrity, performed in a large series of patients with cirrhosis, 
lead us the possibility to unravel the clinical and prognostic relevance of alteration in 
the HSA molecule which occurs during advanced chronic liver disease. Indeed, we 
found that specific pattern of molecular alterations, involving the Cys-34 residue, 
provided of antioxidant activity, but also other molecular sites, were associated to the 
severity of cirrhosis and to the presence of major clinical complication of the disease 
such as ascites, renal impairment and bacterial infection. More interesting, the residual 
amount of the native unchanged HSA, found to be reduced in the more severe patients, 
emerged as a potent predictor of 1-year mortality. Also the functional integrity of the N-
terminal portion of the HSA molecule, provided with an indirect antioxidant activity84, 
was found to be reduced in patients with cirrhosis. Contrary to what observed for the 
structural alteration, the N-terminal functional impairment of the HSA molecule was not 
influenced by the severity of cirrhosis nor by the presence of clinical complication of 
the disease such as ascites or renal impairment, while a strong association was found 
between a reduced chelating activity of HSA and the presence of bacterial infection. 
The first important finding of the present study is that the molecular structure of HSA is 
extensively altered in patients with cirrhosis. Indeed, the HPLC-ESI-MS technique we 
employed, providing a spectrum of molecules with high resolution, discriminating 
between isoforms whose molecular weight differs by few Daltons, allowed an accurate 
characterization of the HSA circulating microheterogeneity in both patients and healthy 
subjects. Among the structural alterations revealed by the mass spectra, the 
cysteinylation was the more frequent. This alteration was found to occur alone or in 
combination with other molecular changes, among which the truncation the of N-
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terminal portion of the molecule and the glycosylation 65-71. This alteration likely results 
from the pro-oxidant environment, which develops in the plasma of patients with 
advanced cirrhosis. Indeed, in this setting circulating cysteine is oxidized to cysteine 
disulfide, which interacts with the free sulfhydryl group at the albumin Cys-34 site 
undergoing a disulfide exchange 85. The cysteinylation of the HSA molecule is therefore 
a result of this reversible oxidation. Since reduced Cys-34 accounts for the vast majority 
of the total plasma free sulfhydryl groups, a significant impairment of the circulating 
antioxidant system can be expected in the case of extensive oxidation85. Indeed the in 
vitro experiments performed in the present study showed that exposure of plasma 
samples to increased concentration of an oxidant agent resulted in an elevation of all 
oxidized albumin isoforms. Confirming these results we found a significant positive 
correlation between all cysteinylated HSA isoforms and the severity of cirrhosis as 
assessed by the MELD and Child Pugh prognostic scores. Indeed oxidative stress is an 
hallmark of chronic liver disease and its extent parallels the severity of cirrhosis, being 
one of the mechanism leading to cell death and organ failure in patient with advanced 
cirrhosis10. 
Higher oxidative modifications to the HSA molecule involving the Cys-34 residue were 
also found, this was the case of the sulfinylation (HSA-SO2H), an irreversible oxidation 
of the free thiol group on the albumin molecule74. This albumin isoforms is a part of the 
non-mercaptalbumin-2 (HNA2) fraction, the amount of which was previously found to 
correlate with the severity of cirrhosis and to predict mortality of patients69. In the 
present study, although slight increased, the relative amount of the HSA-SO2H isoform 
was not significantly affected by the presence of cirrhosis, however it have to be noted 
that cirrhotic patients enrolled in our study were characterized by a less severe cirrhosis 
than patients included in previously reported study, which were mainly characterized by 
the presence of an acute-on chronic liver failure 69. A further oxidative modification of 
HSA molecule resulted from the formation of albumin dimers. Such alteration was 
never reported before in patients with liver cirrhosis, and its occurrence was promoted 
by systemic oxidative stress as suggested by studies performed in other clinical 
settings77. By performing in vitro experiments we confirmed that oxidative stress 
represents the main driver for HSA dimers formation. Indeed, following exposure to a 
pro-oxidant agent, their concentration in plasma samples was found to increase in a time 
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and concentration dependent manner. We also performed additional experiments in 
order to better characterize the HSA molecular site involved in dimerization process. 
The tryptic digestion of plasma samples followed by LC-ESI-MSMS showed that each 
HSA isoforms resulted from the formation of a disulfide bond between two Cys-34 
residue located on two different HSA molecules. Confirming this result the more 
abundant dimeric HSA isoform we found in plasma samples from both healthy controls 
and cirrhotic patients were those characterized by a free Cys-34 residue in their 
monomeric form. Therefore the occurrence of the dimerization process may contribute, 
with the previously reported oxidative modifications, to a further reduction of the 
plasmatic free thiol group pool, thus impairing the defense system against oxidative 
stress. As a matter of the fact all the dimeric isoforms we analyzed significantly 
correlated with both MELD and Child Pugh scores, being their extent an indirect 
marker of the increased oxidative stress which characterizes the more advanced phases 
of cirrhosis.  
Glycosylation of the HSA molecule was also found to significantly contribute to the 
circulating HSA microheterogeneity in both patients and controls. Protein glycosylation 
is a common alteration promoted by glycemic stress86. This alteration affects both 
structure and function of the HSA molecule, impairing its binding and detoxification 
capacity67. The occurrence of protein glycosylation in cirrhotic patients may be 
expected since about one-third of these patients suffer from diabetes mellitus. Indeed we 
found that all glycosylated HSA isoforms (HSA+GLYC; HSA+CYS+GLYC) were 
significantly increased in cirrhotic patients with respect to healthy controls. Further 
analysis revealed that diabetes is the main driver for the occurrence of the HSA+GLYC 
isoform, being this specific alteration significantly elevated only in cirrhotic patients 
with type 2 diabetes mellitus, while the HSA+CYS+GLYC isoform was found to be 
increased in patients irrespective of the presence of diabetes. Consistently with this 
observation, the HSA+CYS+GLYC was found to correlate with the MELD score, while 
an inverse correlation was found between the relative amount of the HSA+GLYC 
isoform and the severity of cirrhosis. The reason for such result mainly resides in the 
peculiar distribution of patients with diabetes enrolled in the study among the Child 
Pugh classes. Indeed diabetic patients were characterized by a less severe cirrhosis in 
our series.  
 68 
 
Finally N- and C-terminal truncated isoforms were also found in plasma samples from 
cirrhotic patients and healthy controls. The N-terminal portion of the HSA molecule is 
provided with an indirect antioxidant activity 30. Indeed, the N-terminal portion of the 
molecule is able to chelate metal ions, thus contributing to the reduction of reactive 
species by binding free Cu (I/II) and Fe (II) metals, which are potent enhancer of the 
production of free radicals 87. On the contrary an impaired protein stability which leads 
to a shortening of the HSA circulating half-life was attributed to the truncation of the C-
terminal portion of the molecule30. While a significant increase of the N-terminal 
truncated and cysteinylated isoform (HSA-DA+CYS) was found in cirrhotic patients 
with respect to healthy controls, the relative abundance of HSA isoform characterized 
only by the truncation of the C- or N- terminal aminoacidic residues did not differ 
between the two groups, being also slight lower in patients than in controls. The reason 
for this discrepancy resides in the fact that, these isoforms are characterized by a free 
Cys-34 residue therefore they may be more susceptible to the dimerization process, and 
indeed dHSA-DA and d-HSA-L were found to be significantly increased in cirrhotic 
patients than in controls, being their relative amount directly correlated to the severity of 
the disease, and, in the case of dHSA-DA, associated to the 1-year mortality. 
Another novel finding of the present study is the association existing between specific 
HSA isoforms and clinical features of cirrhosis, irrespective of the degree of disease 
severity. Indeed specific pattern of HSA molecular structural alteration were found to be 
associated to the most frequent complication of cirrhosis, among which ascites, renal 
impairment and bacterial infection. Monomeric and dimeric HSA isoforms found to be 
associated to these complications were mainly characterized by a reversible or 
irreversible oxidation of the Cys-34 residue, thus underling the relevance of systemic 
oxidative stress in the pathogenesis of event leading to acute decompensation of the 
disease10. On the other hand, it is also reasonable to hypothesize that the pro-oxidant 
and pro-inflammatory environment occurring during these complications, characterized 
by increased protease activity, and a storm of pro-inflammatory cytokine and free 
radical67,88, may favor the multiple structural alterations to the HSA molecule 
demonstrated in the present study. 
As a result of the above described structural abnormalities, the residual amount of the 
native, unchanged HSA isoform was found to be significantly reduced in patients with 
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cirrhosis with respect to healthy controls and additionally its relative amount decreased 
proportionally to the severity of cirrhosis. Being the amount of the residual native HSA 
profoundly influenced by the wide spectrum of structural alteration occurring in 
cirrhotic patients carrying different clinical feature, it is not surprising that the native 
HSA emerged as a better predictor of 1-year survival than total serum albumin 
concentration, which was an established and widely accepted prognostic marker in the 
field of chronic liver disease. In this view, while the total serum albumin concentration 
only reflect the residual functional capacity of the liver, the native HSA encloses 
information regarding both the liver function and systemic redox state which allow to 
better predict middle-term prognosis.   
The evaluation of the residual functional capacity of the N-terminal portion of the HSA 
molecule was carried out through the measurement of the circulating level of Ischemia 
Modified Albumin (IMA). The term Ischemia-Modified Albumin (IMA) identify an 
HSA isoform with a reduced ability to chelate cobalt at the N-terminal region which is 
is a strong binding site for transition metals, including also copper and nickel 89 .IMA 
elevation was initially described during myocardial infarction 90and thereafter during 
other ischemic conditions, such as stroke91 or mesenteric ischemia 92 . IMA elevation 
has been also observed in non-ischemic diseases characterized by enhanced oxidative 
stress, including ketoacidosis 93 or end-stage kidney disease 94. Thus, IMA lacks of 
tissue specificity and reflects a functional disturbance, likely related to a transient 
conformational change at the N-terminus site as a result of hypoxia, acidosis, or free-
radical injury 90 In the present study we found a significant increase of both absolute 
IMA levels and IMA to albumin ratio (IMAr) in patients with cirrhosis with respect to 
healthy controls, however no association were found with the severity of cirrhosis, with 
exception of an expected correlation between IMAr and Child-Pugh score. These results 
were partially at variance with previous reports in which circulating IMAr were 
significantly associated to the MELD score and predict 90-day survival 72. Besides 
differences in the sample size between our and the previous mentioned study 72, it have 
to be noted that in the study from Jalan et al. patients were screened mainly in intensive 
care units and were characterized by the presence of acute-on-chronic liver failure, a 
syndrome associated to a very high mortality rate in the short term 81.  
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Given that results it is not surprising the lack of association between circulating IMA 
and IMAr level and the presence of acute clinical complication of cirrhosis, such as 
ascites and renal impairment. Contrariwise, an interesting finding is represented by the 
specific and strong association between circulating IMA and IMAr level and the 
presence of bacterial infection at hospital admission. Thus the finding of a significant, 
although moderate, increase in IMA level in the whole population of cirrhotic patients 
end the rising of both its absolute value and the ratio IMAr following bacterial infection 
prompt for a role of oxidative stress in the generation of this albumin isoform 
characterized by an impaired chelating function. Indeed, IMA elevation may occurs in 
advanced cirrhosis likely as a result of the chronic pro-oxidant and pro-inflammatory 
state induced by bacterial translocation25. In presence of a clinically-evident bacterial 
infection, which is known to acutely activate the immune response and exacerbate 
systemic inflammation25, a further increase of IMA can be reasonably expected. This 
hypothesis was also confirmed by the experiment performed in rats with experimental 
cirrhosis. Indeed, while cirrhotic rats displayed increased IMA level just at baseline, the 
intravenous administration of a single dose of LPS resulted in a significant rise in IMA 
level at 6 hours only in rats with cirrhosis. Finally, additional evidences of the 
relationship between IMA and bacterial infection derive from the multivariate analysis, 
which showed that IMA level was associated to the infectious complication 
independently from CRP levels, as well as from the ROC curve analysis according to 
which the discriminating performance of IMA level was comparable to that of CRP. It 
have to be noted that the vast majority of the bacterial infection recorded in our 
population were not characterized by systemic involvement, as diagnosis of sepsis was 
carried out only in 6 out of 40 patients with bacterial infection at hospital admission. 
This also explain the fact that procalcitonin levels as well as prognostic scores, such as 
Child-Pugh and MELD scores, were not significantly increased in patients with 
bacterial infection with respect to not infected counterparts. Thus, summarizing such 
results, our data prompt for a potential role of IMA as a new diagnostic biomarker for 
the early detection of localized bacterial infection. 
In conclusion, this study demonstrates that extensive alterations to the HSA molecule, 
involving both structure and function, occurs in patients with cirrhosis. Structural 
alteration involves not only the Cys-34 residue, but also other molecular site, being their 
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extent related to the severity of cirrhosis. Structural alterations were also found to be 
associated to specific clinical complication of the disease, thus contributing to their poor 
prognosis. Indeed, the residual amount of the native, unchanged HSA isoform was 
found to be independently associated to 1-year survival and was characterized by a 
prognostic power higher than the absolute albumin concentration. In the same patients 
circulating HSA was found to be also altered at the functional level as suggested by the 
increased circulating IMA level. Contrary to structural alterations, IMA level was not 
associated to the severity of cirrhosis nor to the patients prognosis, while a rise in its 
circulating level was found following acute event, such as bacterial infection, known to 
enhance the systemic inflammation and oxidative stress.  
Overall the findings provided by the present study strengthens the concept of “effective 
albumin concentration35,95, which implies that a global assessment of the circulating 
albumin pool have to take into account not only its absolute concentration, mainly 
responsible for its oncotic activity, but also its circulating microheterogeneity, and thus 
its structural and functional integrity, responsible for the non-oncotic activity of the 
molecule. 
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